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 Abstract 
Established therapy in Alzheimer’s disease involves potentiation of the endogenous orthosteric 
ligand, acetylcholine, at the M1 muscarinic receptors found in higher concentrations in the cortex 
and hippocampus. Adverse effects, due to indiscriminate activation of other muscarinic receptor 
subtypes, are common. M1 muscarinic positive allosteric modulators/allosteric agonists such as 
BQCA offer an attractive solution, being exquisitely M1-selective over other muscarinic subtypes. 
A common difficulty with allosteric ligands is interpreting SAR, based on composite potency 
values derived in the presence of fixed concentration of agonist. In reality these values encompass 
multiple pharmacological parameters – each potentially, and differentially sensitive to structural 
modification of the ligand. 
We report novel BQCA analogues which appear to augment ligand affinity for the receptor (pKB), 
intrinsic efficacy (τB) and both binding (α) and functional (β) cooperativity with acetylcholine. 
Ultimately, development of such enriched SAR surrounding allosteric modulators will provide 
insight into their mode of action.  
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 INTRODUCTION 
Alzheimer’s disease is a progressively debilitating, neurodegenerative disorder, primarily 
affecting the ageing population. Though first described over 100 years ago, the underlying causative 
factors are yet to be identified. Symptoms include confusion, memory loss and dementia, ultimately 
leading to death. Progressive degeneration of cholinergic neurons in several brain areas, including 
the cerebral cortex and hippocampus, is known to occur. In particular, the muscarinic M1 receptor 
has been found to be more prevalent in these same areas of the brain. 1,2 
Although no disease modifying therapy is currently available, the majority of pharmacotherapy 
provides symptomatic relief through augmentation of cholinergic function, via administration of 
anticholinesterase inhibitors. The undesired effects (e.g. nausea, vomiting, bradycardia) of this type 
of therapy result from indiscriminate augmentation of the endogenous orthosteric ligand; 
acetylcholine (ACh), and subsequent non-selective overactivation of other muscarinic receptor 
subtypes (M2-M5).
3 A selective orthosteric agonist of the M1 receptor is likely to offer better 
therapy, through fewer off-target effects. However, subtype selectivity within the muscarinic 
receptors is notoriously difficult to achieve, primarily due to the highly conserved amino acid 
sequence within the orthosteric site of each muscarinic receptor subtype.4 
More recently, compounds binding to topographically distinct sites on the receptor (allosteric 
sites), able to potentiate the agonist activity of an orthosteric ligand (positive allosteric modulators, 
PAMs), or activate the receptor in their own right as well as potentiating agonist activity (allosteric 
agonists), have been discovered.5 PAMs have the potential to offer a more desirable therapeutic 
profile than classic orthosteric agonists, as they would potentiate endogenous ligand activity (via 
altering affinity, efficacy, or both) under more physiological conditions, rather than the unselective 
and continuous agonist activity conferred by an orthosteric agonist. In addition, the potential for 
subtype selectivity is higher, due to less evolutionary pressure to conserve amino acid sequences 
that are not within the orthosteric site.5 
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 The compound 1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (BQCA), has 
been shown to exhibit unprecedented positive allosteric activity for ACh binding as well as inherent 
agonist activity at the M1 muscarinic receptor. 
6,7 Additionally, BQCA appears to display high 
subtype selectivity, with no activity detected at concentrations up to 100 µM at any of the other four 
muscarinic receptor subtypes, in several assays. 6,8 
Among the previously reported structure-activity relationships (SARs), one study especially 
suggests that the activity of BQCA analogues as M1 muscarinic PAMs is improved by incorporation 
of fluorine atoms at either or both the 5- and 8-positions of the quinolone ring.9 However, all of 
these SAR studies are based on an ‘allosteric potency’ value, determined from titration of the 
modulator in the presence of a fixed (e.g., EC20) concentration of the endogenous ligand, ACh. The 
main issue with such titration curves is that the estimated ‘allosteric potency’ reflects a composite 
of at least four operational properties,10 namely; the affinity of the modulator for the free receptor 
(KB), its allosteric effects on the binding and signalling of the orthosteric ligand (α and β, 
respectively), and its intrinsic agonist efficacy (if any) in the system (τB). In reality, each of these 
parameters may be separately “tuned” through chemical modification, often in opposite directions 
such that minimal changes may be observed in the composite allosteric potency parameter. 
Consequently, use of an all-encompassing allosteric potency value can lead to misinterpretation of 
SAR data. In fact, a common observation in the field, based predominantly on this approach, is that 
allosteric ligand SAR is often “flat”. 5,11 
Our approach to allosteric ligand SAR is based on the premise that a more thorough profiling of 
key-selected compounds would allow us to correlate chemical modifications to each of the 
individual operational parameters of the modulator (affinity, binding/functional cooperativity and 
efficacy). Therefore, using an operational model of allosterism that we have previously described, 
7,10 we sought to quantify the effect of subtle chemical changes on each of the four pharmacological 
parameters, generating an ‘enriched allosteric ligands SAR’ study. 
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 With this in mind, we have synthesised over 35 novel compounds based on the BQCA scaffold 
and introduced four key structural modifications, namely; alternative substitution of the quinolone 
ring in the 5- and 8-positions, isosteric replacement of the carboxylic acid moiety or amide 
derivatives of the acid function and finally, replacement of the N-alkyl group. We characterised 
each of these compounds in radioligand binding experiments to provide affinity and binding 
cooperativity estimates, then investigated the agonist properties of ten of the most effective 
modulators by quantifying their efficacy in an intracellular calcium-mobilization assay. Finally, 
using the same functional assay, we assessed five of the most relevant allosteric agonist analogues 
of BQCA in full interaction studies with ACh to provide functional allosteric modulation estimates. 
With this approach we have been able to better define the key moieties triggering the affinity, 
cooperativity and efficacy of BQCA and its analogues for the M1 muscarinic receptor, in addition to 
gathering some information about the nature of the allosteric binding pocket implicated. By 
generating such enriched allosteric SAR, we believe it is possible to rationally design allosteric 
ligands for GPCRs with tailored characteristics (affinity, cooperativity or agonism). In addition, 
such SAR provides valuable insight into the nature of the target allosteric binding site. 
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 RESULTS AND DISCUSSION 
Chemistry. The 4-oxo-1,4-dihydroquinoline moiety is prevalent in a variety of reported 
compounds, thus its synthesis is well established. Rapid access to series of analogues substituted at 
the 5- and 8-positions of the 4-oxo-1,4-dihydroquinoline ring system was achieved using the 
appropriately substituted aniline as a starting material, utilising Gould-Jacobs chemistry.12 Two 
parallel sets of compounds were easily obtained by variation of the alkyl halide at the N-alkylation 
step, using literature precedent to determine the choice of electrophile.9 
Initial thermal condensation of a variety of 2- or 2,5-disubstituted anilines with commercially 
available diethylethoxymethylene malonate gave substituted (phenylamino)methylene malonates 
1a-d in good yield (Scheme 1). Compounds generally solidified from the neat reaction mixture on 
cooling. Subsequent cyclisation of 1a-d to quinolones 2a-d was carried out with varied yield, by 
heating in the presence of Eaton’s reagent (1:10 w/w P2O5 in methanesulfonic acid). Typically this 
type of cyclisation has been achieved using diphenyl ether as the solvent, requiring high 
temperatures (over 200 °C). 9,13 In addition, diphenyl ether can prove difficult to remove when used 
as a solvent, becoming a viscous liquid or solid on cooling. In comparison, Eaton’s reagent14 offers 
lower temperatures, easy removal (being water miscible) and higher yields.15 Subsequent selective 
N-alkylation proceeded in generally good yield, with crude product precipitating from the reaction 
mixture after addition of water to afford the ester precursors 3a-d and 4a-d. Finally the desired free 
acids 5a-d and 6a-d were obtained after either acidic or basic hydrolysis under standard conditions. 
It was found more aggressive basic hydrolysis of ester 4a resulted in displacement of the 5-F group, 
presumably via a SNAr mechanism, to give phenolic compound 7. 
 
<insert Scheme 1 here> 
 
Amide derivatives of 5,8-difluoro BQCA were obtained through several synthetic routes, starting 
with either carboxylic acid 5a (Scheme 2) or the corresponding ethyl ester 3a (Scheme 3). Although 
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 several amides (8a, 8c, 8d, 8g-h) were obtained after condensation of the appropriate amine with 
the corresponding acid chloride derivative of 5a (not isolated), this method gave generally poor 
yields with several side products. In addition, some N-debenzylation was observed, presumably 
during conversion to the acid chloride, under Vilsmeier-Haack conditions. With the aim of 
improving yields and using milder conditions, the coupling reagent HCTU was employed, with 
DIPEA as a base. This afforded amides (8b, 8e, 8f) in good to excellent yield, with negligible side 
product formation. 
 
<insert Scheme 2 here> 
 
In the case of amides 10a-b and 11, direct aminolysis of ester 3a proved to be a viable option. 
Stirring at room temperature in the presence of MeNH2 (aq), ethanolamine or ammonium hydroxide 
respectively gave the desired products in excellent yields (Scheme 3). 
 
<insert Scheme 3 here> 
 
Compounds bearing established acid isosteric groups were easily accessible via common 
intermediates employed in the synthesis of amide derivatives described above. Condensation of the 
acid chloride intermediate (Scheme 2) with hydroxylamine, gave the corresponding hydroxamic 
acid 8i, whilst using methanesulfonamide in the presence of TEA, gave acylsulfonamide 9, 
following previously reported conditions.16 
Carboxamide 11 was a useful precursor to both the tetrazole 13 and imide 14 (Scheme 3). Initial 
dehydration of 11 in the presence of PdCl2 in MeCN,
17 gave the corresponding nitrile 12. This was 
cyclised with NaN3 to form tetrazole 13 using reported methodology.
18 Acylation of 11 was readily 
achieved with Ac2O/pyridine to give imide 14. 
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<insert Scheme 4 here> 
 
Although compounds bearing different N-alkyl groups could be readily accessed through direct 
N-alkylation of intermediate 2a, as before (Scheme 4); there were several target compounds that 
were not accessible through this route. Construction of the 4-oxo-dihydroquinoline core via a 
tandem addition-elimination mechanism, where a substituted amine nucleophile ultimately forms 
part of the bicyclic core has also been widely reported,9,19 and was employed to synthesise 
derivatives 26a-b, 28, 29, 31 and 32 (Scheme 5). 
To interrogate the environment surrounding the substituted N-benzyl group, positional isomers of 
the literature compound 6a, bearing phenyl substituents in the 2- and 3- position of the benzyl 
pendant were synthesised (16a and 16b, respectively) (Scheme 4). These were readily accessed in 
the same manner as the corresponding 4-phenylbenzyl compound 6a. An additional analogue, 
bearing the 4-(3-aminopropynyl)benzyl group was also made, as this allowed probing of the 4’-
position further incorporating both a linear extension to the ring and a polar, charged head group. 
Initial N-Boc protection of propargyl amine proceeded in excellent yield using mild aqueous 
conditions to give carbamate 18. Subsequent Sonogashira coupling20 in the presence of CuI and 
PdCl2(PPh3)2 afforded the arylalkynyl conjugate 19. The benzylic alcohol group was converted to 
the corresponding benzylic bromide 20 in moderate yield, using standard Appel21 conditions. 
Compound 20 was then used to alkylate ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate (2a) as previously described, giving compound 21. Under aqueous acidic conditions, 
with heating, ester hydrolysis and N-Boc cleavage  of 21 occurred in one step, affording amino acid 
22 as the hydrochloride salt. 
Although similar compounds are present in the quinolone class of antibiotic therapeutics, to our 
knowledge, there are no reported examples of the N-aryl-4-oxo-1,4-dihydroquinoline-3-carboxylic 
acid class possessing allosteric activity at the M1 muscarinic receptor. These compounds were of 
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 interest as they differ from the core BQCA-type structure, only by the absence of the methylene 
group linking the two aromatic moieties. To assess whether such a structure would be viable as an 
M1 allosteric modulator, compounds 26a and 26b were synthesised (Scheme 5). 
 
<insert Scheme 5 here> 
 
The final group of compounds of interest incorporated a piperidin-4-ylmethyl group in 
replacement of the pendant substituted benzyl group (Scheme 5, compounds 28, 29, 30, 31).  
Although similar structures have been incorporated into M1 muscarinic allosteric compounds of the 
quinolizidinone class,5,22-24 to our knowledge, no such moieties have been reported attached to the 
4-oxo-1,4-dihydroquinoline-3-carboxylic acid core. 
Pharmacology. 
According to a previous study utilizing modulator titration curves, the biological activity of 
BQCA analogues as M1 muscarinic PAMs of ACh activity in a calcium mobilisation assay, was 
improved by incorporation of fluorine atoms at the 5- and/or 8-positions of the quinolone ring.9 In 
order to elucidate the effect engendered by the presence of these electronegative atoms on the 
BQCA scaffold, we decided to investigate the effects of the fluorine incorporation on each of the 
four operational parameters describing allosteric modulation by comparing 5a to BQCA (Figure 1, 
Table 1). To assess the binding activity of 5a, we initially performed radioligand binding 
experiments, using M1-expressing CHO cells in the presence of a KD concentration of the 
radiolabelled antagonist [3H]-NMS (0.1 nM), increasing concentrations of ACh with or without 
increasing concentrations of 5a. Such binding interaction studies allowed us to estimate the affinity 
(pKB) of the modulator for the allosteric site of the M1 muscarinic receptor, as well as its binding 
cooperativity (logα) with the endogenous ligand, ACh. Compared to BQCA, the affinity estimate of 
5a (pKB = 4.96 ± 0.13) was very similar to that of BQCA (pKB = 4.72 ± 0.07), and the binding 
cooperativity exerted by 5a on ACh binding (logα = 2.68 ± 0.16; α = 420) was also not significantly 
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 different from that exerted by BQCA (logα = 2.60 ± 0.11; α = 400). Next, we investigated the 
agonist properties of 5a compared to BQCA, in a calcium mobilization assay. As expected, ACh 
was a full agonist in the system, with a potency estimate in the nanomolar range (pEC50 = 8.75 ± 
0.12). Interestingly, both allosteric ligands were full (allosteric) agonists in the M1-expressing CHO 
cells, albeit with lower potency compared to ACh; pEC50 = 6.89 ± 0.11 and 7.50 ± 0.20 for BQCA 
and 5a, respectively. We estimated the efficacy of both modulators in the system. Interestingly, 5a 
appeared to have significantly greater efficacy (logτB = 2.18 ± 0.06; τB = 150) compared to BQCA 
(logτB = 1.45 ± 0.09; τB = 28). Finally, we interacted either BQCA or 5a with ACh in a calcium 
mobilisation assay to estimate the composite cooperativity parameter on binding and function 
(logαβ) in this assay, using an operational model of allosteric agonism. Notably, both BQCA and 
5a, exhibited comparable binding/function cooperativity estimates, with logαβ = 2.72 ± 0.13 (αβ = 
525) and logαβ = 2.31 ± 0.28 (αβ = 205) for BQCA and 5a, respectively. As mentioned previously, 
the ‘allosteric potency’ estimated by generation of titration curves reflects a composite of affinity, 
binding/functional cooperativity and efficacy. Therefore, taken together, these findings suggest that 
the observed improved biological activity of 5a compared to BQCA is predominantly driven by an 
improvement in the agonist properties of the modulator (τB) rather than an improvement of its 
affinity or allosteric properties (pKB or α and β, respectively).  
 
<insert Figure 1 here> 
 
The next phase of this study aimed at investigating the effects of four key structural modifications 
of the BQCA scaffold; alternative substitution of the quinolone ring in the 5- and 8- positions, 
isosteric replacement of the carboxylic acid moiety or amide derivatives of the acid function and 
finally the replacement of the N-alkyl group. Initially, radioligand binding experiments were carried 
out for all ligands, as described above for BQCA and 5a. This allowed us to determine both affinity 
and binding cooperativity estimates for each of the modulators synthesised in this study. Further 
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 functional characterisation in a Ca2+ mobilisation assay was carried out on selected analogues 
exhibiting binding cooperativity with ACh (α) of more than 50-fold. Finally, a small selection of 
allosteric agonist analogues of BQCA (where τB > 100) were investigated further in order to 
estimate the binding/functional cooperativity (log αβ) of each analogue with ACh, thus allowing 
estimates of functional cooperativity (log β) to be extracted. 
First, we investigated the importance of the 5- and 8-fluoro groups on the BQCA scaffold, with 
compounds, 5b-d, 6b-d and 7, as well as the previously reported 5a and 6a. The ester precursors 
3a-d and 4a-d were also incorporated in the study, to determine the role of the carboxylic acid 
functionality. Interestingly, when comparing 5a and the corresponding ester analogue 3a, the 
replacement of the carboxylic acid function by an ethyl ester group did not affect the affinity of the 
analogue for the allosteric site, however had a dramatic effect on the binding cooperativity with 
ACh, such that 3a was virtually incapable of modulating ACh binding (logα = 0.18 ±0.09; α = 1.5). 
Additionally, replacement of the fluorine or hydrogen atoms with methoxy groups, in the ester-
modified analogues of BQCA (3b-d) did not show any improvement in binding cooperativity with 
ACh. Similar results were obtained with the N-(4-phenyl)benzyl analogues (4a-d) with all four 
analogues exhibiting similar affinity estimates to BQCA or 5a, but considerably lower binding 
cooperativity with ACh. In comparison, the corresponding 5- and 8- substituted carboxylic acid 
derivatives (5b-d, 6b-d) exhibited, a different profile of activity. With analogues retaining the N-(4-
methoxy)benzyl group (5b-d), no significant effect was observed on the analogues’ affinity for the 
M1 muscarinic receptor. In contrast, the presence of an 8-OMe group was significantly detrimental 
for the ligand’s binding cooperativity with ACh (compare 5b-c with 5a/5d and BQCA), whereas a 
5-OMe group (5d) had very little effect on the binding cooperativity estimate (compare 5d to 
BQCA). 
Interestingly, replacement of the methoxy group in the R3 position with a phenyl group (6a-d) 
caused a significant increase in the affinity of each analogue for the allosteric site. Similarly to the 
N-(4-methoxy)benzyl series (5a-d), the presence of an 8-OMe group (6b-c) was detrimental for the 
Page 11 of 73
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 ligand’s binding cooperativity with ACh. As before, a 5-OMe group (6d) was better tolerated, 
having less of an effect on the binding cooperativity estimate, compared to 6b and 6c. 
Finally, replacement of the 5-F group of 6a with a phenol moiety in compound 7 resulted in 
around a 0.75 log unit drop in the binding cooperativity estimate, though still being comparable to 
other compounds exhibiting high binding cooperativity estimates (BQCA, 5a, 5d). 
These findings suggest that whilst the carboxylic acid functionality is not essential for ligand 
affinity at the allosteric site (as masking with an ethyl ester group had no significant effect on pKB), 
it appears to be an important determinant of binding cooperativity with ACh. Additionally, 
substitution to a methoxy group in the 8-position is detrimental for the binding cooperativity of the 
ligand; while the same substituent at the 5-position causes relatively less reduction in binding 
cooperativity. The 5-position is able to tolerate hydrogen bond donating (phenol), hydrogen bond 
accepting (fluoro and methoxy) as well as non-hydrogen bonding groups (hydrogen atom). It may 
be of importance to note that the phenolic group in 7 is ideally situated adjacent to the carbonyl 
moiety in the 4-position, allowing a possible intramolecular hydrogen bond interaction to take 
place. This may impact on the ability of the phenolic group to form other interactions (so may only 
be functioning as a hydrogen bond acceptor). 
According to the binding data, apart from BQCA and 5a, the best modulators were 5d, 6a, 6d and 
7, with binding cooperativity (α) equal or higher than 50. We therefore investigated the agonist 
properties of three of these analogues (5d, 6a and 6d). 
All three modulators were full agonists, as observed for 5a, in the calcium mobilisation assay. 
Using an operational model of agonism, we derived estimates of the efficacy of each modulator (5d, 
6a and 6d), in the system. Interestingly, all three analogues exhibited significantly higher efficacy 
estimates than BQCA. Incidentally, when comparing the three analogues to 5a, both 6a and 6d 
exhibited similar efficacy estimates, while 5d was significantly lower than 5a. These findings 
suggest that modifications in the 5- and 8-positions of the BQCA scaffold consistently increase the 
agonistic properties of the modulator, while having very little effect on their ability to modulate 
Page 12 of 73
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 ACh binding. Finally, only one analogue (6a) exhibited an efficacy estimate (logτB = 2.37 ± 0.20; 
τB = 240) higher than 100. We therefore investigated the combined binding/functional cooperativity 
of 6a with ACh in a calcium mobilisation assay. Notably, the combined binding/function 
cooperativity estimate of 6a, was not significantly higher than that of BQCA or 5a, with logαβ = 
2.87 ± 0.24 (αβ = 740). Overall, these findings suggest that modification at the 5- and 8-positions of 
the BQCA scaffold increase the efficacy of the modulators in the system, whereas replacement of 
the N-(4-methoxy)benzyl pendant with N-(4-phenyl)benzyl), increases the affinity of the modulator 
for the allosteric site without affecting the binding cooperativity. 
We then turned our attention to whether the carboxylic acid moiety of the 4-oxo-1,4-
dihydroquinoline-3-carboxylic acid core could be replaced by a group other than an ethyl ester. To 
start, a series of novel amide derivatives, 8a-h, 10a-b and 11 were synthesised, incorporating 
primary amides to bulky tertiary amides. The unsubstituted carboxamide 11 was found to retain 
affinity, but lost an order of magnitude in binding cooperativity with ACh (logα = 1.51 ± 0.12; α = 
32) relative to the parent acid 5a. As mentioned previously, the corresponding ethyl ester 3a 
showed a complete loss of binding cooperativity with ACh, suggesting that the presence of 
hydrogen bond donor functionality in R4 position may be of importance for binding cooperativity 
with the endogenous ligand, rather than the size of the group. Supporting this hypothesis, 
compounds 8d-f and 10b, which also possessed this hydrogen bond donor functionality, retained 
appreciable binding cooperativity with ACh. Of particular interest is 8f (logα = 2.22 ± 0.14; α = 
170) that showed only a small drop in binding cooperativity relative to parent compound 5a, 
demonstrating that an acidic functionality is not essential for the transmission of cooperativity with 
the endogenous ligand. The secondary alcohol group on this compound may be able to make further 
interactions within the allosteric site. Interestingly, 10b, which possessed a hydroxyethyl group and 
should theoretically be able to make a similar type of interaction to 8f, exhibited significantly lower 
binding cooperativity with ACh (logα = 0.96 ± 0.12; α = 9) compared to 8f. This suggests that the 
cyclohexyl ring in 8f is able to either make further desirable contacts with the receptor, or restrain 
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 the hydroxyl moiety in a manner that is energetically favourable, holding the compound in a more 
desirable pose. Notably, the piperidyl analogue 8h also retained appreciable binding cooperativity 
with ACh, though lacks the amide proton. Conversely, methylamide 10a and ethylamide 8a lacked 
appreciable positive binding cooperativity with ACh, suggesting that the presence of a simple 
hydrogen bond moiety alone is not sufficient to explain the effect on binding cooperativity. 
Further investigation of the importance of an acidic moiety at the 3-position of the 4-oxo-1,4-
dihydroquinoline ring was deemed possible through a series of carboxylic acid isosteres. Many of 
these isosteres offer advantages in terms of ADMET properties, whilst also varying in strength of 
acidity. Hydroxamic acid 8i (pKa ~ 8-9),
25 acylsulfonamide 9 (pKa ~ 4.5),
26 tetrazole 13 (pKa ~ 5.4-
7.2)26 and imide 14 (pKa ~ 8-9)
27 were synthesised and evaluated as they vary in both size and 
acidity relative to the parent carboxylic acid 5a (pKa ~ 6-7)
28. In addition, the intermediate nitrile 12 
was screened, though not possessing any inherent acidic functionality. All of the acid isostere 
analogues retained appreciable binding cooperativity with ACh (α > 10). Consistently with what we 
observed in the previous analogues, no significant effect on the analogues affinity estimates was 
noted. Interestingly, the nitrile intermediate 12 suffered almost complete abolition of positive 
binding cooperativity with ACh. When both acid isosteres and amide analogues are compared, it is 
evident that replacement of carboxylic acid is tolerated at the level of the affinity parameter though 
causes a reduction in binding cooperativity with ACh. The pKa of the heteroatom-bonded hydrogen 
does not appear to influence either the ability of binding or the binding cooperativity of the 
modulators for the allosteric site. The possibility to make such replacements offers potential 
improvements from a pharmacokinetic perspective, particularly in terms of intrinsic permeability 
and CNS penetration (generally poor for BQCA-type analogues),8,9,29-31 especially with the 
analogue 8f that appears to retain satisfactory binding affinity and binding cooperativity.  
 
<insert Table 2 here> 
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 According to the binding data, three analogues of 5a exhibit binding cooperativity with ACh, 
higher than 50. These three analogues, 8d, 8f and 13, were therefore selected to investigate their 
ability to induce agonist activity at the M1 muscarinic receptor. We performed concentration-
response curves with all three analogues and estimated the efficacy parameter of each modulator.  
Interestingly, compared to 5a, the substitution of the carboxylic acid with either a benzylamide 8d, 
or a tetrazole 13, had a deleterious effect on the efficacy of the modulator for the receptor with 
logτB = 1.25 ± 0.20; (τB = 18) and logτB = 0.99 ± 0.07; (τB = 10) for 8d and 13, respectively. 
Comparatively, the substitutions with a 2-hydroxylcyclohexylamide, as in 8f, had no significant 
effect on the efficacy of the modulators; with efficacy estimates similar to the one observed for 5a. 
8f being the only analogue that exhibited good efficacy, we interacted this modulator with ACh in a 
calcium-mobiization assay and observed that interestingly, 8f exhibited a combined 
binding/function cooperativity estimate slightly higher than 5a, with logαβ = 2.92 ± 0.06 (αβ = 
840). Thus far 8f appears to be the only compound in this series that appears to exhibit appreciable 
cooperativity through binding and function with ACh in the calcium mobilisation assay. 
 
<insert Table 3 here> 
 
Probing of the N-alkyl pendant seemed prudent, given most of the related compounds reported, 
focussed on a 4-substituted-benzyl group very early in the structural optimisation programme.9,22-
24,30-33 Though compound 6a, that exhibits over 1000-fold potentiation of ACh binding, has been 
previously reported, to our knowledge, the related N-(2-phenyl)benzyl and N-(3-phenyl)benzyl 
analogues are unreported. We synthesised the corresponding analogues 16a-b and an additional 
compound, 22 which probes the 4-position of the N-benzylic pendant in a more linear fashion via an 
aminopropynyl group. Both 16a-b had similar affinity relative to 6a. In terms of binding 
cooperativity, both compounds retain satisfactory cooperativity with ACh, albeit considerably less 
than that observed with 6a, such that over a log unit of cooperativity was lost with 16a and b. The 
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 amino compound 22 retained both affinity and exhibited only small reduction in binding 
cooperativity relative to 5a (to which it is structurally related). Overall, though the 4-position of the 
N-benzylic pendant is still the favoured substitution, both the 2- and 3-phenyl substituted analogues 
offer good affinity and appreciable binding cooperativity with ACh. The apparent ability to 
exchange a variety of groups at the 4-position of the benzylic pendant, whilst retaining good 
binding cooperativity with ACh, indicates the presence of a potentially open pocket within the 
receptor. Compounds 16a and 22 were selected to assess agonist properties. Both exhibited greater 
than 50-fold binding cooperativity with ACh. In contrast, the 2-phenyl analogue 16a, lost most of 
its agonist properties compared to the 4-phenyl analogue 6a (logτB = 1.10 ± 0.23; τB = 13). 
Interestingly, the propargylamine derivative, 22, exhibited just as good efficacy (logτB = 2.29 ± 
0.07; τB = 195) as 5a, its closest related analogue. Interacting 22, the only compound with an 
appreciable efficacy, with ACh in calcium mobilization assay provided a binding/function 
cooperativity estimate nearly identical to the one established for 5a (logαβ = 2.35 ± 0.09; αβ = 225). 
 
 
<insert Table 4 here> 
 
Finally, to further interrogate the N-substituent of the 4-oxo-1,4-dihydroquinoline core, 
compounds removing the methylene linker to the pendant aromatic ring (26a-b) and those replacing 
the aromatic ring with an aliphatic heterocycle were synthesized (28, 29, 31 and 32). Simple 
removal of the methylene linker in 26a-b completely abolished the ability of the analogues to 
transmit cooperativity with ACh, when compared to BQCA. Similarly, all piperidyl-linked 
compounds (28, 29, 31 and 32), which lack aromaticity, exhibited a heavy reduction in binding 
cooperativity with ACh, relative to BQCA. In the case of amine salt 29 and N-benzyl amine 31, 
cooperative binding was completely abolished. However, the bulky urea 32 displayed some 
remaining binding cooperativity with ACh, compared to 29 and 31, suggesting that the loss of 
Page 16 of 73
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 cooperativity with ACh would rather be due to the potential protonation of the amine rather than the 
introduction of a bulky group, though a more extensive set of analogues would need to be 
investigated to establish this hypothesis. Taken together, the N-alkyl and N-aryl series suggest the 
presence of a fairly open pocket removed from the core 4-oxo-1,4-dihydroquinoline structure, 
which is able to tolerate a variety of groups differing in size and polarity. It would appear however, 
that access to this proposed pocket is via a conformationally sensitive linker region, preferring 
planar aromatic groups, hinged through a methylene unit. Indeed, literature would suggest that 
branching or extension of the methylene linker is not tolerated.9 Taken with our findings that 
removal of the linker is not tolerated in terms of retaining binding cooperativity, the methylene 
linker appears thus far to be optimal. 
  
Page 17 of 73
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 CONCLUSIONS 
The pharmacological activity of the prototypical selective M1-Muscarinic PAM/allosteric agonist 
BQCA and related compounds, has only previously been described through an all-encompassing 
‘allosteric potency’ estimate. In reality this estimate is comprised at least four operational 
parameters (KB  - affinity for the receptor; α and β - binding and functional cooperativity factors 
with the orthosteric ligand, respectively; and τB – intrinsic efficacy). With each of these parameters 
being independently tuneable through chemical modification, we first sought to define a robust 
pharmacological profile of BQCA and key related literature compounds 5a and 6a. Building on 
this, we initiated a SAR campaign, synthesising over 35 novel compounds with structural 
modification in four areas: alternative substitution of the 5- and 8- positions of the quinolone ring, 
isosteric replacement of the carboxylic acid moiety or amide derivatives and replacement of the 
pendant N-alkyl group. 
Evaluation of the literature compounds BQCA, 5a and 6a revealed the mechanism through which 
5,8-difluoro analogues display improved biological activity. This was found to be due to an 
increased intrinsic efficacy (τB), relative to BQCA. Related analogues bearing varied 5- and 8- 
substituents (3a-d, 4a-d, 5a-d, 6a-d and 7) on both the carboxylic acid and ester scaffold revealed 
that though the presence of the carboxylic acid group is not essential for affinity, it is important in 
determining the binding cooperativity with ACh. Whilst an 8-methoxy substituent is generally 
detrimental towards binding cooperativity with ACh, the corresponding 5-methoxy substituent is 
better tolerated. Furthermore, the 5-position is able to tolerate both hydrogen bond donating 
(phenol) and accepting (fluoro and methoxy) as well as non-hydrogen bonding groups (hydrogen 
atom), whilst still maintaining appreciable affinity for the receptor and binding cooperativity with 
ACh. Overall, substituents at the 5- and 8- positions seem to be more important in tuning the 
intrinsic efficacy, whereas changing the N-(4-methoxy)benzyl group to N-(4-phenyl)benzyl tended 
to improve affinity for the receptor without improving cooperative binding with ACh. 
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 Our series of novel amide derivatives (8a-h, 10a-b and 11) revealed that the presence of a 
hydrogen bond donor group, rather than a carboxylic acid functionality may be of importance for 
binding cooperativity with ACh, though amide derivatives did suffer a reduction in this parameter 
compared to 5a. Notably, 8f only displayed a small drop in binding cooperativity with ACh, relative 
to parent compound 5a. The presence of a secondary alcohol group on the cyclohexylamide 
substituent may allow for further hydrogen bond or polar interactions. Furthermore, the orientation 
of the amide substituent seems key as the more flexible 10b exhibited significantly reduced binding 
cooperativity with ACh compared to 8f. Further evaluation of 8f revealed it to be the only 
compound in our novel series, which also possessed appreciable functional cooperativity with ACh 
in the calcium mobilisation assay (i.e. log αβ > log α). 
Isosteric replacement of the carboxylic acid group was tolerated at the level of affinity for the 
receptor, but caused a reduction in binding cooperativity with ACh. The pKa of the acidic hydrogen 
atom does not seem to correlate with the degree of cooperative binding with ACh. 
Though the amide and acid isostere derivatives of 5a synthesised to date do not improve binding 
cooperativity with ACh over that observed with 5a, such groups do allow further elaboration of the 
core BQCA scaffold, whilst offering potential improvements in terms of ADMET. Furthermore, our 
findings are in contrast to those recently published,34 which report that functionalization of the 
carboxylic acid moiety on the quinolone-based scaffold is not tolerated. Indeed, amide 8f whilst 
being comparable to the parent acid 5f in terms of affinity for the receptor and binding cooperativity 
with ACh, actually exhibits improved intrinsic efficacy, as well as functional cooperativity with 
ACh in the calcium mobilisation assay. 
Finally, our investigations into the N-alkyl pendant showed that substitution in the 4-position of 
the benzylic group is the most favourable, and seemingly a range of groups can be accommodated. 
Gratifyingly, propargylamine derivative 22 retained a similar pharmacological profile to 5a, 
indicating a potentially open pocket or area able to tolerate a variety of functional groups and 
polarities. However, access to this pocket appears to be tightly controlled, as removal of the 
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 methylene linker in 26a and 26b resulted in complete loss of binding cooperativity with ACh 
without major effect on affinity. The presence of a more bulky aliphatic heterocycle instead of the 
planar aromatic ring present in a benzyl group, again caused severe loss of binding cooperativity 
with ACh over several analogues. This again supports the notion that access to a more open pocket 
is most optimally achieved via a conformationally sensitive linker region, preferring planar 
aromatic groups, hinged through a methylene unit. 
In summary, our detailed pharmacological profiling approach to allosteric ligands for the M1 
muscarinic receptor has demonstrated the subtle tunability of individual ligand parameters through 
chemical modification, which has previously only been described as an overall ‘allosteric potency’ 
estimate. This allows a more enriched understanding of the SAR surrounding allosteric ligands, 
bringing us closer to delineating some of the ‘flat’ SAR often encountered in this field. 
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 EXPERIMENTAL SECTION 
Chemistry. Chemicals and solvents were purchased from standard suppliers and used without 
further purification.  Davisil® silica gel (40-63 µm), for flash column chromatography (FCC) was 
supplied by Grace Davison Discovery Sciences (Victoria, Australia) and deuterated solvents were 
purchased from Cambridge Isotope Laboratories, Inc. (USA, distributed by Novachem PTY. Ltd, 
Victoria, Australia). 
Unless otherwise stated, reactions were carried out at ambient temperature. All microwave 
reactions took place in a Biotage Initiator Microwave Synthesiser. Reactions were monitored by 
thin layer chromatography on commercially available precoated aluminium-backed plates (Merck 
Kieselgel 60 F254).  Visualisation was by examination under UV light (254 and 366 nm).  General 
staining carried out with KMnO4 or phosphomolybdic acid. A solution of Ninhydrin (in ethanol) 
was used to visualize primary and secondary amines. All organic extracts collected after aqueous 
work-up procedures were dried over anhydrous MgSO4 or Na2SO4 before gravity filtering and 
evaporation to dryness.  Organic solvents were evaporated in vacuo at ≤ 40°C (water bath 
temperature).  Purification using preparative layer chromatography (PLC) was carried out on 
Analtech preparative TLC plates (200 mm × 200 mm × 2 mm). 
1H NMR and 13C NMR spectra were recorded on a Bruker Avance Nanobay III 400 MHz 
Ultrashield Plus spectrometer at 400.13 MHz and 100.62 MHz respectively. Chemical shifts (δ) are 
recorded in parts per million (ppm) with reference to the chemical shift of the deuterated solvent.  
Coupling constants (J) and carbon-fluorine coupling constants (JCF) are recorded in Hz and the 
significant multiplicities described by singlet (s), doublet (d), triplet (t), quadruplet (q), broad (br), 
multiplet (m), doublet of doublets (dd), doublet of triplets (dt).  Spectra were assigned using 
appropriate COSY, distortionless enhanced polarisation transfer (DEPT), HSQC and HMBC 
sequences. 
LC-MS were run to verify reaction outcome and purity using an Agilent 6100 Series Single Quad 
coupled to an Agilent 1200 Series HPLC. The following buffers were used; buffer A: 0.1% formic 
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 acid in H2O; buffer B: 0.1% formic acid in MeCN.  The following gradient was used with a 
Phenomenex Luna 3µM C8(2) 15 × 4.6 mm column, and a flow rate of 0.5 mL/min and total run 
time of 12 min; 0–4 min 95% buffer A and 5% buffer B, 4–7 min 0% buffer A and 100% buffer B, 
7–12 min 95% buffer A and 5% buffer B.  Mass spectra were acquired in positive and negative ion 
mode with a scan range of 0–1000 m/z at 5V. UV detection was carried out at 254 nm. All retention 
times (tR) are quoted in minutes. All compounds were of > 95% purity. 
General procedure A: Condensation of substituted anilines with diethylethoxymethylene 
malonate. Aniline and diethylethoxymethylene malonate (1 eq) were heated at 100-120 °C (oil 
bath) together until TLC analysis (EtOAc/PE 3:7) or LC-MS analysis indicated conversion was 
complete (1–7 h). The mixture was cooled to rt, or until precipitation was noted. At this point, the 
mixture was diluted with excess PE, and the resulting precipitate collected by filtration (vacuum), 
before washing with further PE, and drying. 
General procedure B: Cyclisation of substituted diethyl 2-
((phenylamino)methylene)malonates (1a–1d) in Eaton’s reagent, to give corresponding ethyl 
4-oxo-1,4-dihydroquinoline-3-carboxylates. Substituted diethyl 2-
((phenylamino)methylene)malonate was dissolved in Eaton’s reagent (a solution of 
P2O5/methanesulfonic acid 1:10 w/w, 1 mL/mmol) and heated at 90-100 °C (oil bath) under an 
atmosphere of nitrogen gas until TLC analysis (EtOAc) indicated disappearance of starting material 
(5 h to overnight). The mixture was cooled to 5 °C, before pouring into sat. NaHCO3 (aq) and stirring 
for 15 min. The resulting precipitate was isolated by filtration (vacuum) and washed with water, 
then PE, before drying. 
General procedure C: N-Alkylation of substituted ethyl 4-oxo-1,4-dihydroquinoline-3-
carboxylates (2a–2e). Substituted ethyl 4-oxo-1,4-dihydroquinoline-3-carboxylate, K2CO3 (1.1-1.3 
eq), KI (0.1 eq) and the appropriate alkyl halide (1.1-1.3 eq) were stirred in DMF (2-4 mL/mmol) at 
rt overnight. The reaction was monitored by TLC (EtOAc or EtOAc/DCM 8:2). The reaction 
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 mixture was poured onto ice/.water and the resulting precipitate collected by filtration (vacuum), 
with further washings of water, followed by washings of PE, before drying. 
General procedure D: Basic hydrolysis of esters to give corresponding carboxylic acids. The 
appropriate ester was stirred in THF/H2O (1:1, 4–10 mL/mmol), with the vessel atmosphere being 
purged with nitrogen gas. To this was added LiOH.H2O (2-4 eq), and the mixture stirred at rt 
overnight. Once TLC analysis indicated disappearance of the starting material, the reaction mixture 
was diluted with water (to 20 mL) and washed with Et2O (20 mL). The aqueous layer was carefully 
acidified (~pH 3) with 2 M HCl(aq), before extracting with EtOAc (3 × 20 mL). The combined 
organic layers were washed with brine (20 mL), before concentration under reduced pressure. 
General procedure E: Synthesis of amide derivatives of 5,8-difluoro-1-(4-methoxybenzyl)-4-
oxo-1,4-dihydroquinoline-3-carboxylic acid (5a), through an acid chloride intermediate. 5,8-
Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5a) (1.00 g, 2.90 
mmol) was dispersed in anhydrous DCM, under an atmosphere of N2, and cooled to 0 °C, over an 
ice bath. To this was added oxalyl chloride (0.278 mL, 3.19 mmol, 1.1 eq) and DMF (1 drop). The 
mixture was stirred over the ice bath for 15 min, before warming to rt, and stirring for 1 h. Oxalyl 
chloride (0.5 eq) was added, and stirring continued for a further 30 min. One tenth of this batch 
mixture was then added to a vessel containing the appropriate amine (0.725 mmol, 2.5 eq) in DCM 
(3 mL). Where the amine was present as the hydrochloride salt, TEA (0.754 mmol, 2.6 eq) were 
also added. The mixtures were stirred at rt overnight, before diluting with DCM (20 mL), and 
washing with 2 M HCl(aq) (20 mL). After concentration of the organic layers, the crude products 
were further purified by FCC (eluent EtOAc/PE or EtOAc/DCM). 
General procedure F: HCTU-mediated coupling of 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-
1,4-dihydroquinoline-3-carboxylic acid (5a) with amines to give the corresponding amide. 5,8-
Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5a) (100 mg, 0.29 
mmol), HCTU (144 mg, 0.35 mmol, 1.2 eq) and amine (1.2-1.5 eq) where stirred in DMF (2 mL) at 
rt. To this mixture, was added DIPEA (1.5-3 eq, depending on whether the amine was used in the 
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 hydrochloride salt form) in DCM (2 mL), before stirring at rt overnight. DCM was removed from 
the reaction mixture under reduced pressure, before diluting the residue with 1 M HCl(aq) (20 mL), 
and extracting with EtOAc (3 × 20 mL). The combined organic layers were washed with sat. 
NaHCO3 (aq) (30 mL), water (30 mL) and brine (30 mL). After concentration of the organic layers, 
the crude product was further purified by FCC. 
Diethyl 2-(((2,5-difluorophenyl)amino)methylene)malonate (1a).
35
 2,5-Difluoroaniline (11.79 
g, 91.32 mmol) was reacted according to general procedure A to give 22.597 g of off-white 
crystalline solid (83%). 1H NMR (400 MHz, CDCl3) δ 11.06 (d, J = 13.1 Hz, 1H), 8.39 (d, J = 13.3 
Hz, 1H), 7.11 (ddd, J = 10.1/9.1/4.8 Hz, 1H), 7.00 (ddd, J = 9.2/6.3/2.9 Hz, 1H), 6.76 (dddd, J = 
9.0/7.6/3.7/2.9 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H), 4.27 (q, J = 7.1 Hz, 2H), 1.38 (t, J = 7.1 Hz, 3H), 
1.34 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.52, 165.40, 159.33 (dd, JCF = 243.6/2.3 
Hz), 150.08, 148.95 (dd, JCF = 242.1/2.8 Hz), 129.02 (dd, JCF = 12.9/10.3 Hz), 117.17 (dd, JCF = 
21.4/9.7 Hz), 110.83 (dd, JCF = 24.2/7.4 Hz), 103.38 (dd, JCF = 28.4/1.5 Hz), 96.42, 60.90, 60.58, 
14.53, 14.39; m/z MS (TOF ES-) C14H14F2NO4 [M-H]
- calcd 298.1; found 298.0; LC-MS tR: 6.18. 
Diethyl 2-(((5-fluoro-2-methoxyphenyl)amino)methylene)malonate (1b). 5-Fluoro-2-
methoxyaniline (2.17 g, 15.37 mmol) was reacted according to general procedure A to give 3.387 g 
of off-white solid (71%). 1H NMR (400 MHz, CDCl3) δ 11.09 (d, J = 13.5 Hz, 1H), 8.44 (d, J = 
13.9 Hz, 1H), 6.97 (dd, J = 9.4/2.8 Hz, 1H), 6.85 (dd, J = 9.0, 4.8 Hz, 1H), 6.76 (ddd, J = 
8.9/8.0/2.8 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.92 (s, 3H), 1.38 (t, J = 7.1 
Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.45, 165.82, 157.56 (d, JCF = 
239.4 Hz), 149.78, 145.16 (d, JCF = 2.3 Hz), 129.85 (d, JCF = 10.0 Hz), 112.06 (d, JCF = 9.2 Hz), 
110.13 (d, JCF = 23.0 Hz), 102.04 (d, JCF = 27.9 Hz), 95.09, 60.58, 60.37, 56.58, 14.57, 14.44; LC-
MS tR: 6.15. 
Diethyl 2-(((2-methoxyphenyl)amino)methylene)malonate (1c).
36
 ortho-Anisidine (2.00 g, 
16.24 mmol) was reacted according to general procedure A, After reaction completion, addition of 
PE on cooling caused formation of a dark red oily layer at the bottom of the flask. This was stirred 
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 in PE for 5 min, before allowing full separation to occur, and decanting the top layer. The red oil 
was washed with PE in this manner a further two times before drying under vacuum, causing a 
solidification to occur. Filtration (vacuum) gave 1.155 g of light red solid. The decanted PE 
washings began to show crystal formation. These were collected by filtration (vacuum) and washed 
with PE to give 2.958 g of off-white crystals. Spectral comparison of the two solids indicated both 
were the desired product. Total yield: 4.113 g (86%). 1H NMR (400 MHz, CDCl3) δ 11.11 (d, J = 
13.9 Hz, 1H), 8.57 (d, J = 14.0 Hz, 1H), 7.29–7.21 (m, 1H), 7.12–7.07 (m, 1H), 6.99 (ddd, J = 
7.6/7.6/ 0.9 Hz, 1H), 6.94 (dd, J = 8.1/1.2 Hz, 1H), 4.33 (q, J = 7.1 Hz, 2H), 4.25 (q, J = 7.1 Hz, 
2H), 3.94 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H), 1.33 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
168.67, 166.17, 150.55, 149.08, 128.90, 124.94, 121.33, 114.47, 111.38, 93.90, 60.40, 60.19, 56.08, 
14.59, 14.48; m/z MS (TOF ES+) C15H19NNaO5 [M+Na]
+ calcd 316.3; found 316.2; LC-MS tR: 
6.08. 
Diethyl 2-(((2-chloro-5-methoxyphenyl)amino)methylene)malonate (1d). 6-Chloro-m-
anisidine hydrochloride (3.00 g, 15.46 mmol), Et3N (2.37 mL, 17.00 mmol, 1.1 eq) and 
diethylethoxymethylene malonate (3.34 g, 15.46 mmol, 1eq) were stirred together under a reflux 
condenser at 100 °C for 1 h. TLC analysis (EtOAc/PE 3:7) indicated disappearance of starting 
aniline. The mixture was cooled to rt overnight, before partitioning between water (100 mL) and 
Et2O (100 mL). The aqueous layer was extracted with EtOAc (100 mL), and the combined organic 
layers washed with water (100 mL) then brine (50 mL), before drying over MgSO4 and 
concentrating to give a crude purple solid. This was dispersed in PE, sonicated, then filtered 
(vacuum), with washings of PE, to give 4.024 g (79%) of purple solid. 1H NMR (400 MHz, CDCl3) 
δ 11.24 (d, J = 13.1 Hz, 1H), 8.47 (d, J = 13.2 Hz, 1H), 7.31 (d, J = 8.8 Hz, 1H), 6.82 (d, J = 2.7 
Hz, 1H), 6.62 (dd, J = 8.9/2.7 Hz, 1H), 4.34 (q, J = 7.1 Hz, 2H), 4.26 (q, J = 7.1 Hz, 2H), 3.83 (s, 
3H), 1.38 (t, J = 7.1 Hz, 3H), 1.34 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 168.48, 
165.85, 159.62, 150.24, 137.13, 130.80, 115.35, 110.25, 102.05, 95.82, 60.78, 60.49, 55.90, 14.54, 
14.46; m/z MS (TOF ES-) C15H17ClNO5 [M-H]
- calcd 326.8; found 326.0; LC-MS tR: 6.33. 
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 Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (2a).
35 Diethyl 2-(((2,5-
difluorophenyl)amino)methylene)malonate (1a) (26.07 g, 87.12 mmol) was cyclised according to 
general procedure B to give 18.54 g of yellow solid (84%). 1H NMR (400 MHz, DMSO) δ 8.62 (s, 
1H), 7.27 (ddd, J = 10.4/8.8/4.2 Hz, 1H), 6.79 (ddd, J = 12.3/8.7/3.9 Hz, 1H), 4.17 (q, J = 7.1 Hz, 
2H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, DMSO) δ 173.24, 166.79, 156.87 (dd, JCF = 
256.0/2.8 Hz), 153.47, 152.94 (dd, JCF = 247.2/3.7 Hz), 140.68 (d, JCF = 12.5 Hz), 119.64 (d, JCF = 
4.6 Hz), 114.04 (dd, JCF = 21.5/11.1 Hz), 108.79, 106.88 (dd, JCF = 24.5/7.7 Hz), 58.59, 14.46; m/z 
MS (TOF ES-) C12H8F2NO3 [M-H]
- calcd 252.1; found 252.1; MS (TOF ES+) C12H10F2NO3 [MH]
+ 
calcd 254.1; found 254.1; LC-MS tR: 4.55. 
Ethyl 5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2b). Diethyl 2-(((5-
fluoro-2-methoxyphenyl)amino)methylene)malonate (1b) (3.303 g, 10. 61 mmol) was cyclised 
according to general procedure B. On pouring the cooled reaction mixture on to sat. NaHCO3 (aq), 
precipitation did not occur. The aqueous mixture was extracted with EtOAc (3 x 100 mL), and the 
combined organic extracts washed with brine (120 mL). The organic layers were then concentrated 
under reduced pressure to give a crude orange solid. This was redissolved in the minimum amount 
of EtOAc, before adding enough PE to effect precipitation. The resultant solid was collected by 
filtration (vacuum), to give 1.226 g of brown solid (44%). 1H NMR (400 MHz, DMSO) δ 11.81 (d, 
J = 6.0 Hz, 1H), 8.25 (d, J = 6.8 Hz, 1H), 7.27 (dd, J = 8.9/3.8 Hz, 1H), 7.04 (dd, J = 11.9/8.9 Hz, 
1H), 4.20 (q, J = 7.1 Hz, 2H), 3.97 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, DMSO) δ 
172.12, 164.34, 154.32 (d, JCF = 252.6 Hz), 144.55 (d, JCF = 3.5 Hz), 143.62, 130.73 (d, JCF = 3.7 
Hz), 117.11 (d, JCF = 9.6 Hz), 112.47 (d, JCF = 9.6 Hz), 111.70, 109.93 (d, JCF = 22.9 Hz), 59.72, 
56.59, 14.26; m/z MS (TOF ES+) C13H13FNO4 [MH]
+ calcd 266.1; found 266.1; LC-MS tR: 4.75. 
Ethyl 8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2c). Diethyl 2-(((2-
methoxyphenyl)amino)methylene)malonate (1c) (3.97 g, 13.53 mmol) was cyclised according to 
general procedure B. The resulting crude solid was recrystallised from EtOH/water, giving two 
crops: 994 mg of pale brown solid and 944 mg of brown solid. Total yield = 1.938 g (58%).  1H 
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 NMR (400 MHz, DMSO) δ 11.91 (s, 1H), 8.34 (d, J = 5.6 Hz, 1H), 7.71 (d, J = 6.2 Hz, 1H), 7.44 – 
7.26 (m, 2H), 4.21 (q, J = 7.0 Hz, 2H), 4.00 (s, 3H), 1.27 (t, J = 7.0 Hz, 3H); 13C NMR (101 MHz, 
DMSO) δ 173.20, 164.66, 148.71, 144.03, 129.34, 128.17, 124.66, 116.78, 112.24, 109.99, 59.61, 
56.36, 14.33; m/z MS (TOF ES+) C13H14NO4 [MH]
+ calcd 248.3; found 248.1; LC-MS tR: 4.79. 
Ethyl 8-chloro-5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2d).
37
 Diethyl 2-(((2-
chloro-5-methoxyphenyl)amino)methylene)malonate (1d) (3.983 g, 12.15 mmol) was cyclised 
according to general procedure B. On pouring the cooled reaction mixture on to sat. NaHCO3 (aq), 
precipitation did not occur. The aqueous mixture was extracted with EtOAc (3 × 50 mL). TLC 
analysis (EtOAc) of the aqueous and organic layers indicated product was still present in the 
aqueous layer. This was concentrated, and saturated with NaCl, before re-extraction with EtOAc (3 
x 50 mL). Concentration of both organic layers found them to be impure, so they were combined, 
concentrated and further purified by FCC (eluent MeOH/EtOAc/PE 0:50:50 to 0:100:0, then up to 
2:98:0) to give 1.213 g of brown solid (35%). 1H NMR (400 MHz, DMSO) δ 11.36 (s, 1H), 8.23 (s, 
1H), 7.75 (d, J = 8.9 Hz, 1H), 6.90 (d, J = 8.9 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.83 (s, 3H), 1.26 
(t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, DMSO) δ 172.71, 164.49, 159.09, 149.13, 143.24, 132.62, 
121.34, 115.93, 112.29, 106.82, 59.75, 56.09, 14.23; m/z MS (TOF ES+) C13H13ClNO4 [MH]
+ calcd 
282.7; found 282.1; LC-MS tR: 4.88. 
Ethyl 5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2e).
37
 Ethyl 8-chloro-5-methoxy-
4-oxo-1,4-dihydroquinoline-3-carboxylate (2d) (500 mg, 1.78 mmol) was dispersed in EtOH (10 
mL), before sonication to degas the solvent. The vessel was evacuated and filled with nitrogen, 
before addition of 10% Pd/C (50 mg), with care. After resealing, the vessel underwent three cycles 
of evacuation and filling with hydrogen gas (balloon), before stirring at rt overnight. TLC analysis 
(MeOH/DCM 1:9) indicated only partial progression, so EtOH (10 mL) was added to aid 
dissolution of the starting material, and hydrogenation continued for a further 2 nights. After this 
time 10% Pd/C (50 mg) was added with care (after evacuation of the vessel and filling with 
nitrogen gas), and hydrogenation continued. After a total of 5 nights of stirring, no starting material 
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 was evident by TLC. The mixture was diluted with DCM, and filtered through a bed of celite, with 
further washings of DCM. Concentration of the filtrate gave 457 mg of yellow solid (quantitative 
yield). 1H NMR (400 MHz, DMSO) δ 8.36 (s, 1H), 7.58 (dd, J = 8.2/8.2 Hz, 1H), 7.33 (dd, J = 
8.3/0.8 Hz, 1H), 7.15 (dd, J = 8.2/0.6 Hz, 1H), 6.88 (d, J = 8.1 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 
3.82 (s, 3H), 1.27 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, DMSO) δ 173.26, 165.01, 159.78, 
143.15, 141.64, 133.04, 116.86, 111.40, 110.48, 106.35, 59.64, 55.86, 14.28; m/z MS (TOF ES+) 
C13H14NO4 [MH]
+ calcd 248.3; found 248.2; LC-MS tR: 4.53. 
Ethyl 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3a).
8
 
Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (2a) (3.00 g, 11.85 mmol), was 
alkylated with 4-methoxybenzyl chloride, according to general procedure C. After the initial period 
of overnight stirring, further K2CO3 (0.5 eq) and 4-methoxybenzyl chloride (0.5 eq) were added and 
stirring continued for a further overnight period. Due to difficulty filtering the product after pouring 
onto ice water, EtOAc (500 mL) was added to redissolve the wet crude material, and this was 
washed with water (100 mL) and brine (100 mL), before concentration under reduced pressure. 
Crude residue was redissolved in the minimum amount of EtOAc, and precipitation effected by 
addition of PE. The desired product was isolated by filtration (vacuum) to give 3.074 g of brown 
solid (69%). 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 7.32–7.15 (m, 1H), 7.08 (d, J = 8.4 Hz, 
2H), 6.96 (ddd, J = 10.4/9.0/3.4 Hz, 1H), 6.86 (d, J = 8.8 Hz, 2H), 5.43 (d, J = 2.8 Hz, 2H), 4.39 (q, 
J = 7.1 Hz, 2H), 3.78 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.20, 
165.33, 161.99 (d, JCF = 233.7 Hz), 159.88, 151.22, 150.53 (d, JCF = 231.7 Hz), 127.89, 127.88, 
127.17 (d, JCF = 1.0 Hz), 125.16 (d, JCF = 7.5 Hz), 120.04, 114.64, 113.09, 112.30 (d, JCF = 25.2 
Hz), 61.39, 60.64 (d, JCF = 17.3 Hz), 55.46, 14.52; m/z MS (TOF ES
-) C20H17F2NNaO4 [M+Na]
+ 
calcd 396.1; found 396.1; LC-MS tR: 5.62. 
Ethyl 5-fluoro-8-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(3b). Ethyl 5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2b) (200 mg, 0.75 
mmol) was alkylated with 4-methoxybenzyl chloride, according to general procedure C. After the 
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 initial period of overnight stirring, further K2CO3 (0.3 eq) and 4-methoxybenzyl chloride (0.3 eq) 
were added and stirring continued for a further overnight period. The desired product was isolated 
by filtration as described, to give 160 mg of yellow solid (58%). 1H NMR (400 MHz, CDCl3) δ 8.38 
(s, 1H), 7.06–6.88 (m, 4H), 6.87–6.75 (m, 2H), 5.61 (s, 2H), 4.37 (q, J = 7.1 Hz, 2H), 3.76 (s, 3H), 
3.72 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 173.47, 165.68, 159.41, 
156.53 (d, JCF = 258.3 Hz), 151.84, 145.93 (d, JCF = 3.9 Hz), 131.71, 128.78, 127.47, 121.11 (d, JCF 
= 7.1 Hz), 115.03 (d, JCF = 10.2 Hz), 114.41, 112.67, 112.13 (d, JCF = 23.8 Hz), 61.41, 61.15, 
56.79, 55.42, 14.54; m/z MS (TOF ES+) C21H21FNO5 [MH]
+ calcd 386.4; found 386.2; LC-MS tR: 
5.62. 
Ethyl 8-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3c). Ethyl 
8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2c) (500 mg, 2.02 mmol) was alkylated with 
4-methoxybenyl chloride, according to general procedure C, to give 578 mg of pale brown solid. 
This was further purified by FCC (eluent EtOAc/PE 0:100 to 100:0) to give 529 mg of light brown 
solid (71%). 1H NMR (400 MHz, CDCl3) δ 8.47 (s, 1H), 8.16 (dd, J = 8.1/1.3 Hz, 1H), 7.31 (t, J = 
8.0 Hz, 1H), 7.06 (dd, J = 7.9/1.0 Hz, 1H), 6.99 (d, J = 8.7 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 5.66 
(s, 2H), 4.38 (q, J = 7.1 Hz, 2H), 3.75 (s, 6H), 1.40 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 174.06, 165.96, 159.29, 152.08, 150.02, 131.96, 130.27, 129.12, 127.36, 125.67, 120.06, 
114.82, 114.33, 110.83, 61.50, 60.99, 56.37, 55.38, 14.55; m/z MS (TOF ES+) C21H22NO5 [MH]
+ 
calcd 368.4; found 368.2; LC-MS tR: 5.65. 
Ethyl 5-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3d). Ethyl 
5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2e) (100 mg, 0.40 mmol), was alkylated 
with 4-methoxybenzyl chloride, according to general procedure C, to give 66 mg of off-white solid 
(45%). 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 7.41 (dd, J = 8.4/8.4 Hz, 1H), 7.08 (d, J = 8.7 
Hz, 2H), 6.93 – 6.82 (m, 3H), 6.79 (d, J = 8.2 Hz, 1H), 5.24 (s, 2H), 4.38 (q, J = 7.1 Hz, 2H), 3.95 
(s, 3H), 3.78 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.91, 166.36, 
161.75, 159.80, 148.37, 142.00, 132.85, 127.64, 126.42, 119.63, 114.82, 113.30, 108.49, 106.98, 
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 60.98, 57.61, 56.49, 55.47, 14.61; m/z MS (TOF ES+) C21H22NO5 [MH]
+ calcd 368.4; found 368.2; 
LC-MS tR: 5.46. 
Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(4a).
9
 Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (2a) (500 mg, 1.97 mmol), was 
alkylated with 4-phenylbenzyl bromide, according to general procedure C, to give 420 mg of 
yellow solid (51%). 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 7.64–7.49 (m, 4H), 7.48–7.39 (m, 
2H), 7.38–7.30 (m, 1H), 7.29–7.22 (m, 1H), 7.20 (d, J = 8.1 Hz, 2H), 6.97 (ddd, J = 10.3/9.1/3.4 
Hz, 1H), 5.54 (d, J = 2.8 Hz, 2H), 4.40 (q, J = 7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 165.25, 156.74 (d, JCF = 244.7 Hz), 151.39, 147.77 (dd, JCF = 241.9/4.0 Hz), 
141.67, 140.25, 134.33, 130.16, 129.02, 127.96, 127.83, 127.19, 126.65, 120.72 (d, JCF = 7.8 Hz), 
120.06 (dd, JCF = 25.8/10.6 Hz), 113.31, 112.41 (dd, JCF = 24.6, 8.2 Hz), 61.43, 60.83 (d, JCF = 17.2 
Hz), 14.53; m/z MS (TOF ES+) C25H20F2NO3 [MH]
+ calcd 420.4; found 420.2; LC-MS tR: 6.08. 
Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-
carboxylate (4b). Ethyl 5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2b) (500 
mg, 1.89 mmol) was alkylated with 4-phenylbenzyl bromide, according to general procedure C. 
After the initial period of overnight stirring, further K2CO3 (0.3 eq) and 4-phenylbenzyl chloride 
(0.3 eq) were added and stirring continued for a further overnight period. The desired product was 
isolated by filtration as described, to give 258 mg of pale yellow solid (32%).  1H NMR (400 MHz, 
CDCl3) δ 8.41 (s, 1H), 7.62–7.49 (m, 4H), 7.43 (dd, J = 10.3/4.8 Hz, 2H), 7.34 (ddd, J = 7.3/3.8/1.2 
Hz, 1H), 7.12 (d, J = 8.3 Hz, 2H), 7.05 – 6.91 (m, 2H), 5.72 (s, 2H), 4.39 (q, J = 7.1 Hz, 2H), 3.69 
(s, 3H), 1.40 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 173.44, 165.65, 156.58 (d, JCF = 
258.4 Hz), 152.00, 145.89 (d, JCF = 3.9 Hz), 140.94, 140.34, 135.92, 131.75 (d, JCF = 1.6 Hz), 
129.00, 127.72, 127.69, 127.12, 126.31, 121.08 (d, JCF = 7.2 Hz), 115.14 (d, JCF = 10.1 Hz), 112.83, 
112.22 (d, JCF = 23.7 Hz), 61.74, 61.21, 56.82, 14.55; m/z MS (TOF ES
+) C26H23FNO4 [MH]
+ calcd 
432.5; found 432.2; LC-MS tR: 6.08. 
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 Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(4c). Ethyl 8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2c) (500 mg, 2.02 mmol) was 
alkylated with 4-phenylbenzyl bromide, according to general procedure C. After the initial period of 
overnight stirring, further K2CO3 (0.3 eq) and 4-phenylbenzyl chloride (0.3 eq) were added and 
stirring continued for a further overnight period. The desired product was isolated by filtration as 
described, to give 718 mg of yellow solid (86%). 1H NMR (400 MHz, CDCl3) δ 8.51 (s, 1H), 8.20 
(dd, J = 8.1/1.3 Hz, 1H), 7.62–7.47 (m, 4H), 7.42 (dd, J = 7.5/7.5 Hz, 2H), 7.38–7.29 (m, 2H), 7.12 
(d, J = 8.2 Hz, 2H), 7.08 (dd, J = 8.0/1.1 Hz, 1H), 5.77 (s, 2H), 4.41 (q, J = 7.1 Hz, 2H), 3.73 (s, 
3H), 1.42 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.08, 165.99, 152.30, 150.02, 
140.82, 140.40, 136.27, 131.97, 130.36, 128.98, 127.66, 127.64, 127.11, 126.25, 125.79, 120.19, 
114.95, 111.05, 61.86, 61.10, 56.43, 14.59; m/z MS (TOF ES+) C26H24NO4 [MH]
+ calcd 414.5; 
found 414.2; LC-MS tR: 6.12. 
Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(4d). Ethyl 5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate (2e) (250 mg, 1.01 mmol) was 
alkylated with 4-phenylbenzyl bromide, according to general procedure C. The filtered crude solid 
was further purified by FCC (EtOAc/PE 0:100 to 100:0) to give 201 mg of pale yellow solid (48%). 
1H NMR (400 MHz, CDCl3) δ 8.47 (s, 1H), 7.66–7.49 (m, 4H), 7.49–7.39 (m, 3H), 7.39–7.29 (m, 
1H), 7.22 (d, J = 8.4 Hz, 2H), 6.86 (d, J = 8.2 Hz, 1H), 6.81 (d, J = 8.2 Hz, 1H), 5.35 (s, 2H), 4.39 
(q, J = 7.1 Hz, 2H), 3.96 (s, 3H), 1.40 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.88, 
166.28, 161.79, 148.51, 141.99, 141.58, 140.24, 133.59, 132.96, 129.02, 128.09, 127.82, 127.17, 
126.58, 119.59, 113.48, 108.50, 107.06, 61.01, 57.81, 56.51, 14.62; m/z MS (TOF ES+) C26H24NO4 
[MH]+ calcd 414.5; found 414.2; LC-MS tR: 5.98. 
5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5a). Ethyl 
5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3a) (2.37 g, 6.34 
mmol) was dissolved in 1,4-dioxane (15 mL), before adding 2 M HCl(aq). The mixture was heated 
under reflux for 2 h. TLC analysis (EtOAc) indicated complete conversion had taken place. The 
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 mixture was cooled to rt, dilute with water (50 mL) and the precipitate filtered, then washed with 
water and petroleum ether 40-60. The crude collected precipitate was found to contain a mixture of 
the desired acid, as well as some debenzylated derivative. The desired compound was obtained by 
washing the solid with DCM, and concentration of the filtrate. This gave 336 mg (24%) of the 
debenzylated side-product as a white solid (precipitate), and 1.417g (65%) of the desired compound 
as a pale yellow solid (DCM washings). 1H NMR (400 MHz, DMSO) δ 14.76 (s, 1H), 9.11 (s, 1H), 
7.77 (ddd, J = 13.8/9.1/4.4 Hz, 1H), 7.39 (ddd, J = 11.1/9.1/3.2 Hz, 1H), 7.12 (d, J = 8.5 Hz, 2H), 
6.99–6.78 (m, 2H), 5.78 (d, J = 3.7 Hz, 2H), 3.71 (s, J = 4.7 Hz, 3H); 13C NMR (101 MHz, DMSO) 
δ 176.96, 165.21, 158.89, 157.12 (dd, JCF = 261.1/3.1 Hz), 152.20, 147.61 (dd, JCF = 248.1/4.0 Hz), 
130.14 (dd, JCF = 9.0/2.8 Hz), 127.91 (d, JCF = 1.9 Hz), 127.59, 121.86 (dd, JCF = 26.0/10.8 Hz), 
117.51 (d, JCF = 9.1 Hz), 114.17, 113.27 (dd, JCF = 23.6/8.4 Hz), 109.24, 60.22 (d, JCF = 16.5 Hz), 
55.06; m/z MS (TOF ES-) C18H12F2NO4 [M-H]
- calcd 344.3; found 344.1; LC-MS tR: 5.61. 
5-Fluoro-8-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(5b). Ethyl 5-fluoro-8-methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(3b) (121 mg, 0.31 mmol) was hydrolysed according to general procedure D. After initial overnight 
stirring, further LiOH.H2O (1eq) was added, and stirring continued for a further hour before 
workup. The product was isolated as 58 mg of pale brown solid (59%). 1H NMR (400 MHz, 
DMSO) δ 15.07 (s, 1H), 9.04 (s, 1H), 7.45 (dd, J = 9.1, 4.5 Hz, 1H), 7.33 (dd, J = 11.2, 9.1 Hz, 1H), 
7.04 (d, J = 8.7 Hz, 2H), 6.86 (t, J = 5.8 Hz, 2H), 5.94 (s, 2H), 3.79 (s, 3H), 3.69 (s, 3H); 13C NMR 
(101 MHz, DMSO) δ 177.48, 165.54, 158.64, 154.52 (d, JCF = 256.2 Hz), 152.27, 146.40 (d, JCF = 
3.5 Hz), 131.22 (d, JCF = 1.5 Hz), 128.95, 127.65, 117.48 (d, JCF = 8.6 Hz), 117.11 (d, JCF = 9.9 
Hz), 113.99, 113.15 (d, JCF = 22.6 Hz), 108.71, 61.32, 56.89, 55.00; m/z MS (TOF ES
-) 
C19H15FNO5 [M-H]
- calcd 356.1; found 356.0; LC-MS tR: 5.87. 
8-Methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5c). Ethyl 8-
methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3c) (105 mg, 0.29 
mmol) was hydrolysed according to general procedure D. After initial overnight stirring, further 
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 LiOH.H2O (1.5 eq) was added, and stirring continued for a further overnight period before workup. 
In this case, the acidifed aqueous layer was extracted with DCM (3 x 20 mL) to obtain the free acid. 
The product was isolated as 109 mg of pale brown solid (98%). 1H NMR (400 MHz, CDCl3) δ 
14.95 (s, 1H), 8.74 (s, 1H), 8.16 (dd, J = 8.1/1.4 Hz, 1H), 7.47 (dd, J = 8.1 Hz, 1H), 7.21 (dd, J = 
8.0/1.3 Hz, 1H), 7.06–6.90 (m, 2H), 6.88–6.72 (m, 2H), 5.80 (s, 2H), 3.83 (s, 3H), 3.77 (s, 3H); 13C 
NMR (101 MHz, CDCl3) δ 178.35, 167.12, 159.63, 151.30, 150.46, 130.88, 129.22, 128.23, 
127.53, 126.98, 119.17, 115.89, 114.55, 108.76, 62.54, 56.55, 55.44; m/z MS (TOF ES+) 
C19H18NO5 [MH]
+ calcd 340.1; found 340.2; LC-MS tR: 5.67. 
5-Methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5d). Ethyl 5-
methoxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3d) (49 mg, 0.13 mmol) 
was hydrolysed according to general procedure D. After initial overnight stirring, further LiOH.H2O 
(1 eq) was added, and stirring continued for a further hour before workup. The product was isolated 
as 22 mg of yellow solid (49%). 1H NMR (400 MHz, CD3CN) δ 8.83 (s, 1H), 7.65 (dd, J = 8.5 Hz, 
1H), 7.30 – 7.12 (m, 3H), 7.02 (d, J = 8.3 Hz, 1H), 6.90 (d, J = 8.7 Hz, 2H), 5.48 (s, 2H), 3.93 (s, 
3H), 3.75 (s, 3H); 13C NMR (101 MHz, CD3CN) δ 180.60, 167.96, 162.24, 160.73, 149.65, 143.38, 
135.54, 129.30, 127.57, 117.63, 115.37, 110.63, 110.28, 108.69, 58.64, 57.00, 55.99; m/z MS (TOF 
ES+) C19H18NO5 [MH]
+ calcd 340.1; found 340.2; LC-MS tR: 5.34. 
1-([1,1'-Biphenyl]-4-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(6a).
38
 Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(4a) (100 mg, 0.24 mmol) was dispersed in 1,4-dioxane/1M HCl(aq) (1:1, 2 mL) and heated at 80 °C 
for 3.5 h, before stirring at rt overnight. The mixture was then refluxed for a further 2.5 h, before 
TLC analysis (MeOH/DCM 2:98) indicated starting material had been consumed. The mixture was 
diluted with water, and the resultant precipitate collected by filtration (vacuum), before washing 
with further water and PE, then drying. This gave 82 mg of pale yellow solid (88%). 1H NMR (400 
MHz, DMSO) δ 14.79 (s, 1H), 9.19 (s, 1H), 7.79 (ddd, J = 13.8, 9.1, 4.4 Hz, 1H), 7.70–7.52 (m, 
4H), 7.50– 7.31 (m, 4H), 7.26 (d, J = 8.2 Hz, 2H), 5.92 (d, J = 3.9 Hz, 2H); 13C NMR (101 MHz, 
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 DMSO) δ 177.04, 165.23, 157.18 (d, JCF = 262.1 Hz), 152.57, 147.37 (d, JCF = 293.5 Hz), 139.60, 
139.47, 135.62 (d, JCF = 2.1 Hz), 130.29, 128.93, 127.56, 127.06, 126.61, 126.37, 122.04 (dd, JCF = 
22.5, 11.6 Hz), 117.55 (d, JCF = 9.0 Hz), 113.31 (dd, JCF = 23.3, 8.5 Hz), 109.40, 60.44 (d, JCF = 
15.9 Hz); m/z MS (TOF ES+) C23H16F2NO3 [MH]
+ calcd 392.3; found 392.1; LC-MS tR 6.05. 
1-([1,1'-Biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic 
acid (6b). Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-
carboxylate (4b) (214 mg, 0.50 mmol) was hydrolysed according to general procedure D. After 
initial overnight stirring, further LiOH.H2O (1 eq) was added, and stirring continued for a further 
hour before workup. The isolated product was found to contain a small amount of starting material, 
so the crude product was dispersed in 1,4-dioxane/H2O (1:1, 2 mL), and heated at 80 °C for 3.5 
hour, followed stirring at rt overnight, then reflux for 8.5 h. The desired product was isolated by 
filtration, after dilution of the reaction mixture with water, to give 156 mg of pink solid (77%).  1H 
NMR (400 MHz, DMSO) δ 15.08 (s, 1H), 9.09 (s, 1H), 7.69–7.55 (m, 4H), 7.51 – 7.40 (m, 3H), 
7.39 – 7.28 (m, 2H), 7.18 (d, J = 8.3 Hz, 2H), 6.06 (s, 2H), 3.75 (s, 3H); 13C NMR (101 MHz, 
DMSO) δ 177.54, 165.55, 154.60 (d, JCF = 256.2 Hz), 152.58, 146.37 (d, JCF = 3.4 Hz), 139.46, 
139.20, 136.60, 131.36, 128.91, 127.50, 126.85, 126.54, 126.48, 117.53, 117.29 (d, JCF = 10.1 Hz), 
113.20 (d, JCF = 22.9 Hz), 108.81, 61.67, 56.95; m/z MS (TOF ES
+) C24H19FNO4 [MH]
+ calcd 
404.1; found 404.2; LC-MS tR: 6.06. 
1-([1,1'-Biphenyl]-4-ylmethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(6c). Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(4c) (310 mg, 075 mmol), was hydrolysed by the same procedure, as described for the hydrolysis of 
ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(4b) in the synthesis of 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (6b) above. The crude product after acidic hydrolysis required 
washings of DCM/PE (1:1) to remove residual starting material. The title compound was isolated as 
180 mg of white solid (62%). 1H NMR (400 MHz, DMSO) δ 15.16 (s, 1H), 9.14 (s, 1H), 8.01 (dd, J 
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 = 8.0, 1.4 Hz, 1H), 7.67 – 7.53 (m, 5H), 7.48 (dd, J = 8.1, 1.3 Hz, 1H), 7.43 (dd, J = 7.6, 7.6 Hz, 
2H), 7.38–7.30 (m, 1H), 7.18 (d, J = 8.3 Hz, 2H), 6.10 (s, 2H), 3.80 (s, 3H); 13C NMR (101 MHz, 
DMSO) δ 177.50, 165.82, 152.15, 150.35, 139.47, 139.21, 136.78, 130.28, 128.90, 128.06, 127.49, 
127.27, 126.86, 126.54, 126.50, 117.59, 116.71, 107.65, 61.54, 56.60; m/z MS (TOF ES+) 
C24H20NO4 [MH]
+ calcd 386.1; found 386.2; LC-MS tR: 6.15. 
1-([1,1'-Biphenyl]-4-ylmethyl)-5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(6d). Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(4d) (140 mg, 0.34 mmol), was hydrolysed by the same procedure, as described for the hydrolysis 
of ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-
carboxylate (4b) in the synthesis of 1-([1,1'-biphenyl]-4-ylmethyl)-5-fluoro-8-methoxy-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (6b) above. The title compound was isolated as 118 mg of pale 
yellow solid (90%). 1H NMR (400 MHz, DMSO) δ 9.22 (s, 1H), 7.74 (dd, J = 8.5 Hz, 1H), 7.68–
7.55 (m, 4H), 7.44 (dd, J = 7.6 Hz, 2H), 7.39–7.24 (m, 4H), 7.10 (d, J = 8.3 Hz, 1H), 5.84 (s, 2H), 
3.90 (s, 3H); 13C NMR (101 MHz, DMSO) δ 178.84, 166.37, 160.71, 149.46, 141.88, 139.74, 
139.44, 134.89, 134.70, 128.93, 127.59, 127.17, 127.04, 126.61, 115.96, 109.86, 108.68, 107.90, 
56.73, 56.29; m/z MS (TOF ES+) C24H20NO4 [MH]
+ calcd 386.1; found 386.2; LC-MS tR: 5.82. 
1-([1,1'-Biphenyl]-4-ylmethyl)-8-fluoro-5-hydroxy-4-oxo-1,4-dihydroquinoline-3-carboxylic 
acid (7). Ethyl 1-([1,1'-biphenyl]-4-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate (4a) (102 mg, 0.24 mmol) was dispersed in 1 M NaOH (aq)/1,4-dioxane (1:1, 2mL) and 
heated at 80 °C for 3.5 h, followed by stirring at rt overnight. After this time, complete conversion 
to the acid had been achieved. The mixture was heated under reflux for a further 30 h, with no 
appreciable progress noted. LiOH.H2O (41 mg, 1.22 mmol, 5.1 eq) were added and reflux 
continued overnight, followed by stirring at rt for a further week. After this time, the entire mixture 
was transferred to a microwave vial, and LiOH.H2O (5 eq) added. The vessel was sealed, and 
heated at 160 °C for 1 h. LC-MS analysis after this time indicated complete conversion to the title 
compound. The mixture was diluted with water (20 mL) and washed with Et2O (20 mL), before 
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 acidification with 2 M HCl (aq). The resultant precipitate was collected by filtration (vacuum), to 
give 75 mg of yellow/brown solid. This was recrystallised from EtOAc, to give 49 mg of off-white 
solid (53%). 1H NMR (400 MHz, DMSO) δ 13.37 (s, 1H), 13.29 (s, 1H), 9.17 (s, 1H), 7.78–7.54 
(m, 5H), 7.45 (dd, J = 7.6 Hz, 2H), 7.35 (dd, J = 7.3 Hz, 1H), 7.25 (d, J = 8.1 Hz, 2H), 6.87 (dd, J = 
9.0, 3.2 Hz, 1H), 5.89 (d, J = 3.0 Hz, 2H); 13C NMR (101 MHz, DMSO) δ 180.38, 164.38, 157.74 
(d, JCF = 1.8 Hz), 153.29, 143.26 (d, JCF = 240.5 Hz), 139.62, 139.47, 135.58 (d, JCF = 1.6 Hz), 
128.92, 128.47, 127.55, 127.05, 126.61, 126.42, 123.44 (d, JCF = 24.7 Hz), 114.04, 111.99 (d, JCF = 
7.7 Hz), 107.97 (d, JCF = 1.9 Hz), 60.38 (d, JCF = 14.9 Hz); m/z MS (TOF ES
+) C23H17FNO4 [MH]
+ 
calcd 390.1; found 390.1; LC-MS tR: 5.93. 
N-Ethyl-5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (8a). 
The title compound was obtained through condensation of 2M ethylamine in THF with the acid 
chloride intermediate described in general procedure E, to give 40 mg of white solid (37%). 1H 
NMR (400 MHz, CDCl3) δ 9.77 (s, 1H), 8.80 (s, 1H), 7.35–7.26 (m, 1H), 7.08 (d, J = 8.3 Hz, 2H), 
7.00 (ddd, J = 10.8, 9.0, 3.4 Hz, 1H), 6.87–6.79 (m, 2H), 5.52 (d, J = 2.9 Hz, 2H), 3.77 (s, 3H), 3.49 
(qd, J = 7.3, 5.6 Hz, 2H), 1.26 (t, J = 7.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 175.71, 163.89, 
159.90, 158.69 (dd, JCF = 262.2, 2.7 Hz), 150.44, 147.81 (d, JCF = 283.9 Hz), 129.35, 127.98, 
127.19, 120.14 (d, JCF = 11.5 Hz), 119.83, 114.60, 113.82, 111.97 (dd, JCF = 24.4, 8.3 Hz), 61.00 
(d, JCF = 17.1 Hz), 55.44, 34.35, 14.98; m/z MS (TOF ES
+) C20H18F2N2NaO3 [MH]
+ calcd 395.1; 
found 395.1; LC-MS tR: 5.70. 
5,8-Difluoro-1-(4-methoxybenzyl)-N,N-dimethyl-4-oxo-1,4-dihydroquinoline-3-carboxamide 
(8b). The title compound was obtained through coupling of dimethylamine hydrochloride with 5,8-
difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5a), as described in 
general procedure F. FCC purification (eluent MeOH/DCM 1:99 to 2:98) gave 112 mg of pale 
yellow oil that solidified on standing to a yellow solid (quantitative yield). 1H NMR (400 MHz, 
CDCl3) δ 7.92 (s, 1H), 7.23 (ddd, J = 13.6, 6.6, 2.8 Hz, 1H), 7.09 (d, J = 8.4 Hz, 2H), 6.91 (ddd, J = 
10.5, 9.0, 3.3 Hz, 1H), 6.87 – 6.78 (m, 2H), 5.39 (d, J = 2.6 Hz, 2H), 3.75 (s, 3H), 3.08 (s, 3H), 3.03 
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 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 171.80, 166.31, 159.75, 158.44 (dd, JCF = 260.5, 1.7 Hz), 
147.82 (dd, JCF = 246.0, 4.4 Hz), 147.18, 130.60 (dd, JCF = 8.2, 2.8 Hz), 127.98 (d, JCF = 1.4 Hz), 
127.52 (d, JCF = 1.0 Hz), 121.17, 119.59 (d, JCF = 10.7 Hz), 119.33 (d, JCF = 8.6 Hz), 114.54, 
111.08 (dd, JCF = 24.6, 8.2 Hz), 60.01 (d, JCF = 17.2 Hz), 55.38, 38.77, 35.61; m/z MS (TOF ES
+) 
C20H19F2N2O3 [MH]
+ calcd 373.1; found 373.2; LC-MS tR: 4.92. 
5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-N-phenyl-1,4-dihydroquinoline-3-carboxamide 
(8c). The title compound was obtained through condensation of aniline with the acid chloride 
intermediate described in general procedure E, to give 47 mg of white solid (39%). 1H NMR (400 
MHz, CDCl3) δ 11.97 (s, 1H), 8.89 (s, 1H), 7.77 (dd, J = 8.6, 1.0 Hz, 2H), 7.41–7.28 (m, 3H), 7.16–
7.00 (m, 4H), 6.90–6.80 (m, 2H), 5.56 (d, J = 2.8 Hz, 2H), 3.77 (s, 3H); 13C NMR (101 MHz, 
CDCl3) δ 175.78, 162.07, 160.01, 158.73 (dd, JCF = 266.7, 4.2 Hz), 150.79, 148.03 (dd, JCF = 247.2, 
3.6 Hz), 138.61, 130.27, 129.08, 128.09, 126.95, 124.22, 120.68, 120.36 (dd, JCF = 26.2, 10.7 Hz), 
119.71 (d, JCF = 7.4 Hz), 114.69, 113.79, 112.37 (dd, JCF = 24.9, 8.2 Hz), 61.24 (d, JCF = 17.5 Hz), 
55.45; m/z MS (TOF ES+) C24H19F2N2O3 [MH]
+ calcd 421.1; found 421.1; LC-MS tR: 6.12. 
N-Benzyl-5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
(8d). The title compound was obtained through condensation of benzylamine with the acid chloride 
intermediate described in general procedure E, to give 49 mg of white solid (39%). 1H NMR (400 
MHz, CDCl3) δ 10.18 (t, J = 5.4 Hz, 1H), 8.83 (s, 1H), 7.47–7.19 (m, 7H), 7.08 (d, J = 8.4 Hz, 2H), 
7.00 (ddd, J = 10.8, 9.0, 3.4 Hz, 1H), 6.91–6.76 (m, 2H), 5.52 (d, J = 2.9 Hz, 2H), 4.65 (d, J = 5.8 
Hz, 2H), 3.77 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 175.69, 164.13, 159.93, 158.76 (dd, JCF = 
244.7, 2.6 Hz), 150.63, 147.88 (d, JCF = 263.1 Hz), 138.62, 129.50 (d, JCF = 10.1 Hz), 128.75, 
128.00, 127.99, 127.34, 127.12 (d, JCF = 1.2 Hz), 120.12 (dd, JCF = 25.8, 10.7 Hz), 119.84 (d, JCF = 
7.4 Hz), 114.62, 113.64, 112.08 (dd, JCF = 24.6, 8.6 Hz), 61.06 (d, JCF = 17.3 Hz), 55.44, 43.61; m/z 
MS (TOF ES+) C25H21F2N2O3 [MH]
+ calcd 435.2; found 435.1; LC-MS tR: 5.99. 
5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-N-(piperidin-1-yl)-1,4-dihydroquinoline-3-
carboxamide (8e). The title compound was obtained through coupling of 1-aminopiperidine with 
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 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5a), as described 
in general procedure F. FCC purification (eluent MeOH/DCM 0:100 to 5:95), followed PLC 
purification (MeOH/DCM 2:98, plate run 3 times) gave 77 mg of off-white solid (62%). 1H NMR 
(400 MHz, CDCl3) δ 10.58 (s, 1H), 8.81 (s, 1H), 7.36–7.26 (m, 1H), 7.14–6.94 (m, 3H), 6.89–6.76 
(m, 2H), 5.53 (d, J = 2.9 Hz, 2H), 3.77 (s, 3H), 3.09–2.68 (m, 4H), 1.88–1.65 (m, 4H), 1.47 (d, J = 
5.2 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 175.34, 161.54, 159.92, 158.73 (d, JCF = 257.5 Hz), 
150.65, 147.95 (d, JCF = 242.2 Hz), 128.66 (d, JCF = 5.6 Hz), 127.97, 127.13, 120.05 (d, JCF = 5.2 
Hz), 119.76 (d, JCF = 6.7 Hz), 114.61, 113.78, 112.07 (dd, JCF = 24.7, 8.3 Hz), 61.08 (d, JCF = 16.9 
Hz), 57.18, 55.44, 25.25, 23.64; m/z MS (TOF ES+) C23H24F2N3O3 [MH]
+ calcd 428.2; found 428.2; 
LC-MS tR: 5.21. 
5,8-Difluoro-N-((1S,2S)-2-hydroxycyclohexyl)-1-(4-methoxybenzyl)-4-oxo-1,4-
dihydroquinoline-3-carboxamide (8f). The title compound was obtained through coupling of 
(1S,2S)-2-aminocyclohexanol hydrochloride with 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid (5a), as described in general procedure F. FCC purification 
(eluent EtOAc/PE 0:100 to 100:0) gave 148 mg of off-white solid (quantitative yield).  1H NMR 
(400 MHz, CDCl3) δ 9.99 (d, J = 6.9 Hz, 1H), 8.80 (s, 1H), 7.39–7.17 (m, 1H), 7.14–6.94 (m, 3H), 
6.93 – 6.73 (m, 2H), 5.52 (d, J = 2.7 Hz, 2H), 4.07 (s, 1H), 3.91 – 3.67 (m, 4H), 3.58–3.37 (m, 1H), 
2.19–1.95 (m, 2H), 1.83–1.68 (m, 2H), 1.53–1.27 (m, 4H); 13C NMR (101 MHz, CDCl3) δ 175.63, 
165.92, 159.94, 156.41 (d, JCF = 238.8 Hz), 150.80, 145.47 (d, JCF = 255.7 Hz), 130.24 (dd, JCF = 
8.7, 1.9 Hz), 127.97, 127.03, 120.26 (dd, JCF = 25.4, 10.5 Hz), 119.71 (d, JCF = 7.5 Hz), 114.64, 
113.06, 112.25 (dd, JCF = 24.9, 8.2 Hz), 76.11, 61.14 (d, JCF = 17.1 Hz), 55.97, 55.44, 38.75, 34.48, 
31.49, 24.83, 24.10; m/z MS (TOF ES+) C24H25F2N2O4 [MH]
+ calcd 443.2; found 443.2; LC-MS tR: 
5.32;  

 = + 498° (0.0105, DCM).  
5,8-Difluoro-1-(4-methoxybenzyl)-3-(morpholine-4-carbonyl)quinolin-4(1H)-one (8g). 5,8-
difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (5a) (100 mg, 0.29 
mmol) was dispersed in dry DCM (1 mL) under an atmosphere of N2 and cooled to 0 °C, over an 
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 ice bath. To this was added oxalyl chloride (0.028 mL, 0.32 mmol, 1.1 eq) and DMF (1 drop) and 
the mixture stirred on the ice bath for 10 min, before warming to rt and stirring for a further 20 min. 
TLC analysis (EtOAc) indicated starting material had been consumed. Morpholine (0.053 mL, 0.61 
mmol, 2.1 eq) was added, and the mixture stirred for 10 min at rt, before diluting with DCM (20 
mL) and washing with 0.5 M HCl (aq) (20 mL) and sat. NaHCO3 (aq) (20 mL). After concentration of 
the organic layer under reduced pressure, the crude was further purified by FCC (eluent EtOAc 
10:90 to 100:0) to give 100 mg of colourless glassy solid (83%). 1H NMR (400 MHz, DMSO) δ 
8.35 (s, 1H), 7.66–7.49 (m, 1H), 7.22–7.00 (m, 3H), 6.95–6.80 (m, 2H), 5.52 (d, J = 3.2 Hz, 2H), 
3.70 (s, 3H), 3.67–3.53 (m, 6H), 3.40–3.19 (m, 2H); 13C NMR (101 MHz, DMSO) δ 170.90, 
164.13, 158.74, 158.71 (d, JCF = 235.1 Hz), 146.88, 146.86 (d, JCF = 260.9 Hz), 130.37 (d, JCF = 3.4 
Hz), 128.82, 127.30, 120.50 (d, JCF = 6.2 Hz), 119.91 (d, JCF = 2.4 Hz), 114.15, 111.51, 110.76 (dd, 
JCF = 22.5/9.0 Hz), 66.47, 66.05, 58.74 (d, JCF = 15.3 Hz), 55.04, 47.10, 41.99; m/z MS (TOF ES
-) 
C22H21F2N2O4 [M+H]
+ calcd 415.2; found 415.2; LC-MS tR: 5.27. 
5,8-Difluoro-1-(4-methoxybenzyl)-3-(piperidine-1-carbonyl)quinolin-4(1H)-one (8h). The 
title compound was obtained through condensation of piperidine with the acid chloride intermediate 
described in general procedure E, to give 45 mg of off-white semisolid (38%). 1H NMR (400 MHz, 
CDCl3) δ 7.88 (s, 1H), 7.26–7.16 (m, 1H), 7.09 (d, J = 8.5 Hz, 2H), 6.91 (ddd, J = 10.5, 9.0, 3.3 Hz, 
1H), 6.87 – 6.80 (m, 2H), 5.39 (d, J = 2.5 Hz, 2H), 3.77 (s, 3H), 3.69 (s, 2H), 3.36 (s, 2H), 1.83–
1.43 (m, 6H); 13C NMR (101 MHz, CDCl3) δ 171.91, 164.51, 159.77, 158.51 (dd, JCF = 261.8, 2.9 
Hz), 147.84 (dd, JCF = 246.0, 4.4 Hz), 146.82, 130.66 (dd, JCF = 8.1, 2.8 Hz), 128.00, 127.99, 
127.62, 121.38, 119.41 (dd, JCF = 25.6, 10.7 Hz), 114.56, 111.24, 111.00 (dd, JCF = 24.6, 8.2 Hz), 
60.01 (d, JCF = 17.2 Hz), 55.41, 48.75, 43.45, 26.64, 25.69, 24.62; m/z MS (TOF ES
+) 
C23H23F2N2O3 [MH]
+ calcd 413.2; found 413.2; LC-MS tR: 5.55. 
5,8-Difluoro-N-hydroxy-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide 
(8i). The title compound was obtained through condensation of hydroxylamine hydrochloride with 
the acid chloride intermediate described in general procedure E. The crude product was dissolved in 
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 the minimum amount of MeOH, before addition of EtOAc, causing precipitation of a pink solid to 
occur. This was collected by filtration (vacuum) to give 19 mg of the desired compound (18%, > 
90% pure). 1H NMR (400 MHz, DMSO) δ 11.46 (s, 1H), 9.28 (s, 1H), 8.89 (s, 1H), 7.75 – 7.54 (m, 
1H), 7.33 – 7.18 (m, 1H), 7.07 (d, J = 8.5 Hz, 2H), 6.89 (d, J = 8.7 Hz, 2H), 5.71 (d, J = 3.1 Hz, 
2H), 3.70 (s, 3H); 13C NMR (101 MHz, DMSO) δ 173.59, 161.53, 160.37 (d, JCF = 250.8 Hz), 
158.80, 150.21, 147.49 (d, JCF = 244.2 Hz), 129.96 (dd, JCF = 6.6, 1.7 Hz), 128.48, 127.45, 120.54 
(dd, JCF = 26.3, 9.9 Hz), 118.58 (d, JCF = 7.9 Hz), 114.19, 112.56, 112.04 (dd, JCF = 23.3, 8.1 Hz), 
59.55 (d, JCF = 16.2 Hz), 55.05; m/z MS (TOF ES
+) C18H15F2N2O4 [MH]
+ calcd 361.1; found 361.1; 
LC-MS tR: 5.51. 
5,8-Difluoro-1-(4-methoxybenzyl)-N-(methylsulfonyl)-4-oxo-1,4-dihydroquinoline-3-
carboxamide (9).  5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic 
acid (5a) (100 mg, 0.29 mmol) was dispersed in dry DCM  (1 mL) under an atmosphere of N2 and 
cooled to 0 °C, over an ice bath. To this were added oxalyl chloride (0.028 mL, 0.32 mmol, 1.1 eq) 
and DMF (1 drop) and the mixture stirred on the ice bath for 10 min, before stirring at rt for 30 min. 
Oxalyl chloride (0.2 eq) was added, and stirring continued at rt for 10 min. The mixture was 
concentrated under reduced pressure, before redissolving in dry DCM (1 mL) and 
methanesulfonamide (28 mg, 0.29 mmol, 1 eq). The mixture was cooled over an ice bath, under an 
atmosphere of N2, before adding TEA (0.121 mL, 0.87 mmol, 3 eq). The mixture was warmed to rt, 
and left to stir overnight, before diluting with DCM (20 mL) and washing with 1 M HCl(aq) (20 
mL). The organic layer was concentrated and the residue purified by FCC (eluent EtOAc/PE 0:100 
to 100:0) to give 48 mg of white crystalline solid (39%) 1H NMR (400 MHz, CDCl3) δ 12.61 (s, 
1H), 8.72 (s, 1H), 7.39 (ddd, J = 13.5, 9.0, 4.3 Hz, 1H), 7.18–7.01 (m, 3H), 6.95–6.77 (m, 2H), 5.56 
(d, J = 2.8 Hz, 2H), 3.79 (s, 3H), 3.36 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 175.36, 163.08, 
160.28, 159.30 (d, JCF = 240.6 Hz), 151.09, 147.11 (d, JCF = 278.8 Hz), 129.65, 128.35, 126.04, 
121.39 (dd, JCF = 13.6, 10.8 Hz), 121.15, 114.89, 113.63 (d, JCF = 12.6 Hz), 111.19, 61.62 (d, JCF = 
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 17.6 Hz), 55.49, 41.97; m/z MS (TOF ES+) C19H16F2N2NaO5S [M+Na]
+ calcd 445.1; found 445.1; 
LC-MS tR: 5.32. 
5,8-Difluoro-1-(4-methoxybenzyl)-N-methyl-4-oxo-1,4-dihydroquinoline-3-carboxamide 
(10a). Ethyl 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3a) (100 
mg, 0.27 mmol) was stirred in a mixture of EtOH/40% MeNH2 (aq) (1:1, 2 mL) at rt overnight. TLC 
analysis (EtOAc/DCM 1:1) indicated complete conversion had taken place. The mixture was 
poured on to ice water, and the resulting precipitate collected by filtration (vacuum), before drying 
to give 80 mg of pale yellow solid (83%). 1H NMR (400 MHz, CDCl3) δ 9.72 (d, J = 3.7 Hz, 1H), 
8.80 (s, 1H), 7.38–7.19 (m, 1H), 7.07 (d, J = 8.4 Hz, 2H), 7.00 (ddd, J = 10.8, 9.1, 3.3 Hz, 1H), 6.83 
(d, J = 8.7 Hz, 2H), 5.52 (d, J = 2.7 Hz, 2H), 3.77 (s, 3H), 2.99 (d, J = 4.9 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 175.64, 164.76, 159.91, 158.68 (dd, JCF = 262.7, 2.8 Hz), 150.35, 147.88 (d, JCF = 
259.7 Hz), 130.33 (dd, JCF = 8.0, 2.4 Hz), 127.98 (d, JCF = 1.5 Hz), 127.18 (d, JCF = 1.0 Hz), 120.03 
(dd, JCF = 25.7, 11.0 Hz), 119.86 (d, JCF = 7.4 Hz), 114.61, 113.79, 111.98 (dd, JCF = 24.8, 8.2 Hz), 
60.98 (d, JCF = 17.2 Hz), 55.43, 26.10; m/z MS (TOF ES
+) C19H16F2N2NaO3 [M+Na]
+ calcd 381.1; 
found 381.2; LC-MS tR: 5.16. 
5,8-Difluoro-N-(2-hydroxyethyl)-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-
carboxamide (10b). Ethyl 5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylate (3a) (100 mg, 0.27 mmol) was stirred in a mixture of EtOH/ethanolamine (2:1, 3 mL) 
at rt for 3.75 h. TLC analysis (EtOAc) indicated only partial progression, so EtOH (2 mL) was 
added to aid further dissolution. After overnight stirring, complete conversion had taken place. The 
mixture was poured on to ice/2 M HCl (aq), and the resulting precipitate collected by filtration 
(vacuum), with washings of water. After drying, 91 mg of yellow solid was obtained (88%). 1H 
NMR (400 MHz, CDCl3) δ 10.17 (s, 1H), 8.79 (s, 1H), 7.31 (ddd, J = 13.6, 9.0, 4.3 Hz, 1H), 7.14–
6.96 (m, 3H), 6.91–6.78 (m, 2H), 5.52 (d, J = 2.8 Hz, 2H), 3.83 (s, 2H), 3.77 (s, 3H), 3.63 (dd, J = 
10.0, 5.6 Hz, 2H), 3.37 (d, J = 4.5 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 175.60, 165.93, 159.96, 
157.29 (d, JCF = 273.1 Hz), 150.58, 147.96 (d, JCF = 245.2 Hz), 130.28 (d, JCF = 8.5 Hz), 127.98 (d, 
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 JCF = 1.5 Hz), 127.02 (d, JCF = 1.1 Hz), 120.25 (dd, JCF = 25.6, 11.0 Hz), 119.74 (d, JCF = 7.7 Hz), 
114.65, 113.21, 112.25 (dd, JCF = 24.7, 8.1 Hz), 63.43, 61.11 (d, JCF = 17.1 Hz), 55.44, 43.16; m/z 
MS (TOF ES+) C20H19F2N2O4 [MH]
+ calcd 389.1; found 389.2; LC-MS tR: 4.90. 
5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (11). Ethyl 
5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (3a) (520 mg, 1.39 
mmol) was dispersed in 28-30% NH3 (aq)/EtOH (1:1, 8 mL) and stirred at rt in a closed vessel for 60 
h. TLC analysis (EtOAc) indicated complete conversion had taken place. The mixture was diluted 
with water and stirred for 10 min, before collecting the resulting precipitate by filtration (vacuum), 
and drying to give 423 mg (88%) of white solid. 1H NMR (400 MHz, CDCl3) δ 9.50 (s, 1H), 8.79 
(s, 1H), 7.30 (ddd, J = 13.6/9.0/4.3 Hz, 1H), 7.08 (d, J = 8.2 Hz, 2H), 7.02 (ddd, J = 10.7/9.0/3.4 
Hz, 1H), 6.88 – 6.80 (m, 2H), 5.75 (s, 1H), 5.51 (d, J = 2.9 Hz, 2H), 3.77 (s, 3H); 13C NMR (101 
MHz, CDCl3) δ 175.41, 165.80, 159.92, 158.69 (d, JCF = 262.4 Hz), 151.03, 147.98 (d, JCF = 246.8 
Hz), 130.37 (dd, JCF = 8.6/2.9 Hz), 127.92, 127.90, 127.08, 120.26 (dd, JCF = 25.8/10.7 Hz), 119.87 
(d, JCF = 7.2 Hz), 114.62, 113.42, 112.30 (dd, JCF = 24.8/8.4 Hz), 61.10 (d, JCF = 16.9 Hz), 55.44; 
m/z MS (TOF ES+) C18H14F2N2NaO3 [M+Na]
+ calcd 367.3; found 367.1; LC-MS tR: 5.38. 
5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carbonitrile (12). 5,8-
Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (11) (104 mg, 0.30 
mmol) was stirred in MeCN/H2O/MeOH (3:3:1, 7 mL) at rt, before adding PdCl2 (20 mg, 0.12 
mmol, 0.4 eq). The mixture was stirred at rt for 2 h, before adding THF (2 mL) and continuing 
stirring at rt overnight. TLC analysis (EtOAc) indicated partial reaction progression, so stirring was 
continued at 50 °C for a further overnight period, before adding in PdCl2 (0.1 eq) and continuing 
stirring at 50 °C for a final overnight period. After this, organic solvents were removed under 
reduced pressure, and the residue diluted with water (20 mL), before extraction with DCM (3 x 20 
mL). The combined organic extracts were washed with brine (30 mL), before concentration under 
reduced pressure. The crude product was further purified by FCC (eluent EtOAc/PE 0:100 to 100:0) 
to give 34 mg of off-white solid (35%). 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.35 (ddd, J = 
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 13.7, 9.1, 4.4 Hz, 1H), 7.12 (d, J = 8.4 Hz, 2H), 7.05 (ddd, J = 10.0, 9.1, 3.4 Hz, 1H), 6.96–6.82 (m, 
2H), 5.44 (d, J = 2.9 Hz, 2H), 3.81 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 172.03, 160.35, 160.02 
(dd, JCF = 257.5, 6.9 Hz), 150.26, 147.99 (dd, JCF = 247.6, 4.3 Hz), 130.12 (dd, JCF = 6.7, 3.5 Hz), 
128.58, 125.91, 121.20 (dd, JCF = 26.0, 10.4 Hz), 118.47 (d, JCF = 8.5 Hz), 115.01, 114.68, 113.24 
(dd, JCF = 24.0, 8.4 Hz), 98.65, 60.87 (d, JCF = 18.3 Hz), 55.52; m/z MS (TOF ES
+) 
C18H12F2N2NaO2 [M+Na]
+ calcd 349.1; found 349.1; LC-MS tR: 5.20. 
5,8-Difluoro-1-(4-methoxybenzyl)-3-(1H-tetrazol-5-yl)quinolin-4(1H)-one (13). 5,8-Difluoro-
1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carbonitrile (12) (34 mg, 0.20 mmol), NaN3 
(20 mg, 0.31 mmol, 3 eq) and triethylammonium chloride (43 mg, 0.31 mmol, 3eq) were heated 
with stirring in toluene (5 mL) at 100 °C overnight. TLC analysis (EtOAc) indicated no progress, so 
further triethylammonium chloride (143 mg, 10 eq) and NaN3 (67 mg, 10 eq) were added, and 
heating continued under reflux for a further overnight period. TLC analysis indicated almost 
complete conversion, so heating under reflux was continued for a further 7 h, then reduced to 70 °C 
over the weekend. The mixture was cooled, then diluted with Et2O (10 mL) and extracted with 
water (2 x 10 mL). The aqueous layer was washed with Et2O (10 mL), before acidifying with 2M 
HCl (aq) and extracting with EtOAc (2 x 10 mL). Concentration of the EtOAc layers followed by 
PLC purification (MeOH/DCM 5:95, plate run twice) gave 14 mg of yellow solid (38%). 1H NMR 
(400 MHz, CDCl3) δ 14.22 (s, 1H), 9.00 (s, 1H), 7.40 (ddd, J = 13.6, 9.0, 4.3 Hz, 1H), 7.20–7.01 
(m, 3H), 6.96–6.72 (m, 2H), 5.61 (d, J = 2.4 Hz, 2H), 3.78 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 
176.71, 160.18, 158.50 (dd, JCF = 266.5, 3.1 Hz), 150.66, 148.30 (d, JCF = 271.9 Hz), 146.61, 
130.12 (d, JCF = 11.1 Hz), 128.13, 126.55, 120.80 (dd, JCF = 26.1, 10.9 Hz), 118.73 (d, JCF = 8.7 
Hz), 114.83, 113.01 (dd, JCF = 23.9, 7.6 Hz), 106.86, 61.34 (d, JCF = 17.8 Hz), 55.48; m/z MS (TOF 
ES-) C18H12F2N5O2 [M-H]
- calcd 368.1; found 368.0; LC-MS tR: 5.10. 
N-Acetyl-5,8-difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (14). 
5,8-Difluoro-1-(4-methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (11) (50 mg, 0.15 
mmol) was dissolved in pyridine (1 mL), before adding Ac2O (0.021 mL, 0.22 mmol, 1.5 eq) and 
Page 43 of 73
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 stirring at rt overnight. TLC analysis (EtOAc) indicated no progress, so Ac2O (1 mL) and DCM (1 
mL) were added, and stirring continued at rt overnight. The temperature was then increased to 100 
°C, and after 2 d the starting material had disappeared. The mixture was cooled, diluted with water, 
and stirred for 30 min at rt. The resulting precipitate was collected by filtration (vacuum) and 
washed with water and PE. The crude solid was further purified by FCC (eluent EtOAc/PE 0:100 to 
100:0) to give 37 mg of off-white solid (64%). 1H NMR (400 MHz, CDCl3) δ 12.27 (s, 1H), 8.77 (s, 
1H), 7.36 (ddd, J = 13.5, 9.0, 4.3 Hz, 1H), 7.16–7.01 (m, 3H), 6.95–6.80 (m, 2H), 5.55 (d, J = 2.8 
Hz, 2H), 3.78 (s, 3H), 2.46 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 175.41, 171.69, 162.89, 160.16, 
158.71 (dd, JCF = 264.1, 3.1 Hz), 151.64, 147.98 (d, JCF = 247.4 Hz), 130.10 (dd, JCF = 9.3, 2.5 Hz), 
128.18, 126.45, 120.95 (dd, JCF = 26.0, 10.5 Hz), 119.72 (d, JCF = 7.7 Hz), 114.80, 113.14 (dd, JCF 
= 25.0, 8.4 Hz), 112.28, 61.45 (d, JCF = 17.5 Hz), 55.47, 26.39; m/z MS (TOF ES
+) 
C20H16F2N2NaO4 [M+Na]
+ calcd 409.1; found 409.1; LC-MS tR: 5.26. 
Ethyl 1-([1,1'-biphenyl]-2-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(15a). Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (2a) (500 mg, 1.97 mmol), was 
alkylated with 2-(bromomethyl)biphenyl, according to general procedure C. The resulting crude 
product was further purified by FCC (eluent EtOAc/PE 0:100 to 20:80) to give 480 mg (73%) of 
pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.19 (s, 1H), 7.58–7.21 (m, 8H), 7.16 (ddd, J = 
13.5/9.0/4.3 Hz, 1H), 7.02–6.83 (m, 2H), 5.42 (d, J = 2.7 Hz, 2H), 4.35 (q, J = 7.1 Hz, 2H), 1.37 (t, 
J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.35, 164.99, 158.52 (dd, JCF = 263.1/2.7 Hz), 
151.17, 147.66 (dd, JCF = 246.9/4.3 Hz), 141.06, 139.89, 133.07 (d, JCF = 2.1 Hz), 130.75, 130.24 
(d, JCF = 5.7 Hz), 128.82, 128.78, 128.32, 128.23, 127.90, 125.61, 120.52 (d, JCF = 7.7 Hz), 119.83 
(dd, JCF = 25.6/10.5 Hz), 113.04, 112.13 (dd, JCF = 24.7/8.1 Hz), 61.22, 59.55 (d, JCF = 16.9 Hz), 
14.48; m/z MS (TOF ES+) C25H20F2NO3 [M+H]
+ calcd 420.1; found 420.2; LC-MS tR: 6.06. 
Ethyl 1-([1,1'-biphenyl]-3-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(15b). Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (2a) (500 mg, 1.97 mmol), was 
alkylated with 3-phenylbenzyl bromide, according to general procedure C. The resulting crude 
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 product was further purified by FCC (eluent EtOAc/PE 0:100 to 20:80) to give 619 mg (75%) of 
pale yellow solid. 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 7.58–7.47 (m, 3H), 7.47–7.31 (m, 
5H), 7.29–7.17 (m, 1H), 7.07 (d, J = 7.7 Hz, 1H), 6.96 (ddd, J = 10.0, 9.3, 3.4 Hz, 1H), 5.56 (d, J = 
2.9 Hz, 2H), 4.39 (q, J = 7.1 Hz, 2H), 1.40 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
172.48, 165.17, 158.68 (dd, JCF = 263.2/2.6 Hz), 151.38, 147.76 (dd, JCF = 246.5/4.5 Hz), 142.40, 
140.39, 136.04 (d, JCF = 1.4 Hz), 130.11 (d, JCF = 10.7 Hz), 129.74, 129.06, 127.91, 127.48, 127.26, 
124.92, 124.80, 120.65 (d, JCF = 7.5 Hz), 120.07 (dd, JCF = 25.5/10.7 Hz), 113.26, 112.40 (dd, JCF = 
24.7/8.3 Hz), 61.39, 61.05 (d, JCF = 16.9 Hz), 14.50; m/z MS (TOF ES
+) C25H20F2NO3 [MH]
+ calcd 
420.1; found 420.2; LC-MS tR: 6.09. 
1-([1,1'-Biphenyl]-2-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(16a). Ethyl 1-([1,1'-biphenyl]-2-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(15a) (100 mg, 0.24 mmol) was dispersed in 1,4-dioxane/2 M HCl (aq) (1:1, 2 mL) and heated at 80 
°C for 5 h. TLC analysis (EtOAc) indicated complete hydrolysis had taken place. The mixture was 
cooled to rt, before diluting with water (20 mL) and extracting with DCM (3 × 20 mL). 
Concentration of the combined organic layers gave 90 mg of pale yellow solid (96%).  1H NMR 
(400 MHz, CDCl3) δ 14.32 (s, 1H), 8.48 (s, 1H), 7.50–7.27 (m, 7H), 7.23–7.16 (m, 2H), 7.09 (ddd, 
J = 10.2/9.1/3.4 Hz, 1H), 6.94 (d, J = 7.7 Hz, 1H), 5.58 (d, J = 3.0 Hz, 2H); 13C NMR (101 MHz, 
CDCl3) δ 177.71, 165.83, 158.24 (dd, JCF = 265.1/2.7 Hz), 151.52, 147.94 (dd, JCF = 248.7/4.5 Hz), 
141.25, 139.69, 132.10 (d, JCF = 2.1 Hz), 131.07, 131.03, 129.02, 128.87, 128.59, 128.33, 128.13, 
126.25 (d, JCF = 1.6 Hz), 121.35 (dd, JCF = 25.6/10.8 Hz), 118.33 (d, JCF = 9.2 Hz), 113.19 (dd, JCF 
= 23.98.0 Hz), 110.22, 60.87 (d, JCF = 16.9 Hz); m/z MS (TOF ES
+) C23H16F2NO3 [MH]
+ calcd 
392.1; found 392.1; LC-MS tR: 6.00. 
1-([1,1'-Biphenyl]-3-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(16b). Ethyl 1-([1,1'-biphenyl]-3-ylmethyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate 
(15b) (101 mg, 0.24 mmol) was dispersed in 1,4-dioxane/0.2 M HCl (aq) (1:1, 2 mL) and heated at 
60 °C for 3 h. TLC analysis (EtOAc/DCM 1:1) indicated no progress. Heating was continued at 80 
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 °C for a further 1.25 h, before adding in 2M HCl (aq) (0.15 mL). Heating was continued at 80 °C for 
a further 1.75 h, followed by rt stirring overnight. After a final 6 h of heating under reflux, the 
mixture was cooled, diluted with water, and the resulting precipitate collected by filtration 
(vacuum), with washings of water and PE. After drying, 85 mg of pale yellow solid was obtained 
(91%). 1H NMR (400 MHz, DMSO) δ 14.78 (s, 1H), 9.18 (s, 1H), 7.78 (ddd, J = 13.8/9.1/4.4 Hz, 
1H), 7.68–7.56 (m, 3H), 7.54 (s, 1H), 7.50–7.31 (m, 5H), 7.09 (d, J = 7.7 Hz, 1H), 5.94 (d, J = 3.9 
Hz, 2H); 13C NMR (101 MHz, DMSO) δ 177.06, 165.24, 157.16 (dd, JCF = 261.6/2.3 Hz), 152.57, 
147.26 (dd, JCF = 232.5/7.8 Hz), 140.62, 139.60, 137.16 (d, JCF = 2.4 Hz), 130.32 (dd, JCF = 
12.0/2.8 Hz), 129.46, 128.95, 127.67, 126.73, 126.18, 124.61, 124.33, 121.88 (dd, JCF = 25.7/10.3 
Hz), 117.55 (d, JCF = 10.0 Hz), 113.26 (dd, JCF = 23.2/9.0 Hz), 109.40, 60.70 (d, JCF = 15.3 Hz); 
m/z MS (TOF ES+) C23H16F2NO3 [MH]
+ calcd 392.1; found 392.1; LC-MS tR: 6.05. 
tert-Butyl prop-2-yn-1-ylcarbamate (18). Propargylamine (17) (5.126 g, 93.06 mmol) was 
dissolved in water (100 mL) with stirring. To this was added Boc2O (21.325 g, 97.71 mmol, 1.05 
eq), and the mixture was stirred at rt overnight. TLC analysis (MeOH/DCM 1:9) indicated complete 
conversion. The mixture was extracted with DCM (3 × 30 mL), and the combined organic extracts 
washed with water (50 mL). Concentration of the organic layers gave 13.902 g of pale yellow oil, 
which rapidly crystallised to off-white crystals (96%). 1H NMR (400 MHz, CDCl3) δ 4.70 (s, 1H), 
3.92 (d, J = 3.0 Hz, 2H), 2.21 (t, J = 2.5 Hz, 1H), 1.45 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 
146.90, 85.32, 80.21, 71.38, 28.48, 27.57. 
tert-Butyl (3-(4-(hydroxymethyl)phenyl)prop-2-yn-1-yl)carbamate (19).
39
 4-Iodobenzyl 
alcohol (2.02 g, 8.55 mmol), tert-butyl prop-2-yn-1-ylcarbamate (18) (1.724 g, 11.11 mmol, 1.3 eq) 
and TEA (3.573 mL, 25.64 mmol, 3 eq) were placed in a flask in dry THF (20 mL), and degassed 
by sonication (10 min). CuI (82 mg, 0.43 mmol, 0.05 eq) and PdCl2(PPh3)2 (302 mg, 0.43 mmol, 
0.05 eq) were added, and the mixture stirred at rt overnight. TLC analysis (EtOAc/PE 3:7) indicated 
complete depletion of the alkyne. The mixture was diluted with EtOAc (100 mL), before filtering 
through a bed of celite (vacuum). The filtrate was washed with water (2 x 50 mL) and brine (50 
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 mL), before concentration and further purification by FCC (eluent EtOAc/PE 0:100 to 30:70) to 
give 933 mg of light brown solid (42%). 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.2 Hz, 2H), 
7.30 (d, J = 8.4 Hz, 2H), 4.77 (s, 1H), 4.69 (d, J = 5.5 Hz, 2H), 4.15 (d, J = 4.7 Hz, 2H), 1.76 (t, J = 
5.8 Hz, 1H), 1.47 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 150.57, 141.26, 132.02, 126.89, 122.08, 
85.55, 83.07, 71.61, 65.05, 31.35, 28.52; m/z MS (TOF ES+) C11H12NO3 [M-
tBu+2H]+ calcd 206.1; 
found 206.2; LC-MS tR: 5.54. 
tert-Butyl (3-(4-(bromomethyl)phenyl)prop-2-yn-1-yl)carbamate (20). tert-Butyl (3-(4-
(hydroxymethyl)phenyl)prop-2-yn-1-yl)carbamate (19) (880 mg, 3.37 mmol) and CBr4 (1.227 g, 
3.70 mmol, 1.1 eq) were dissolved in DCM (20 mL), before cooling over an ice bath. PPh3 (970 
mg, 3.70 mmol, 1.1 eq) was added, and the mixture allowed to warm to rt with stirring. After 1.5 h 
of stirring at rt, TLC analysis (EtOAc/PE 3:7) indicated good progression. PPh3 (0.5 eq) was added, 
and stirring continued overnight. The mixture was concentrated under reduced pressure, and the 
crude residue further purified by FCC (eluent EtOAc/PE 0:100 to 30:70) to give 595 mg of shiny 
off-white solid (55%). 1H NMR (400 MHz, CDCl3) δ 7.40–7.34 (m, 2H), 7.34–7.27 (m, 2H), 4.75 
(s, 1H), 4.46 (s, 2H), 4.14 (d, J = 4.7 Hz, 2H), 1.46 (s, 9H); 13C NMR (101 MHz, CDCl3) δ 155.40, 
137.97, 132.16, 129.08, 122.98, 86.40, 82.68, 79.62, 32.96, 31.31, 28.46; m/z MS (TOF ES+) 
C11H11BrNO2 [M-
tBu+2H]+ calcd 268.0; found 268.0; LC-MS tR: 6.29. 
Ethyl 1-(4-(3-((tert-butoxycarbonyl)amino)prop-1-yn-1-yl)benzyl)-5,8-difluoro-4-oxo-1,4-
dihydroquinoline-3-carboxylate (21). Ethyl 5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-
carboxylate (2a) (199 mg, 0.79 mmol), was alkylated with tert-butyl (3-(4-
(bromomethyl)phenyl)prop-2-yn-1-yl)carbamate (20), according to general procedure C. The 
resulting crude product was further purified by FCC (eluent EtOAc/PE 5:95 to 100:0) to give 392 
mg (67%) of yellow solid 1H NMR (400 MHz, CDCl3) δ 8.39 (s, 1H), 7.38 (d, J = 8.3 Hz, 2H), 7.22 
(ddd, J = 13.5/9.0/4.3 Hz, 1H), 7.05 (d, J = 8.1 Hz, 2H), 6.96 (ddd, J = 10.3/9.1/3.4 Hz, 1H), 5.47 
(d, J = 2.8 Hz, 2H), 4.74 (s, 1H), 4.39 (q, J = 7.1 Hz, 2H), 4.13 (d, J = 4.5 Hz, 2H), 1.46 (s, 9H), 
1.40 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.42, 165.20, 158.68 (d, JCF = 265.5 Hz), 
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 155.40, 151.31, 147.68 (d, JCF = 243.2 Hz), 135.53 (d, JCF = 1.3 Hz), 132.55, 129.99, 126.07, 
123.28, 120.66 (d, JCF = 7.8 Hz), 120.06 (dd, JCF = 25.5/10.5 Hz), 113.40, 112.49 (d, JCF = 33.3 
Hz), 86.70, 82.33, 80.26, 61.46, 60.80 (d, JCF = 17.0 Hz), 31.30, 28.50, 14.51; m/z MS (TOF ES
+) 
C27H27F2N2O5 [MH]
+ calcd 497.2; found 497.2; LC-MS tR: 5.90. 
1-(4-(3-Aminoprop-1-yn-1-yl)benzyl)-5,8-difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic 
acid hydrochloride (22). Ethyl 1-(4-(3-((tert-butoxycarbonyl)amino)prop-1-yn-1-yl)benzyl)-5,8-
difluoro-4-oxo-1,4-dihydroquinoline-3-carboxylate (21) (230 mg, 0.46 mmol) was dispersed in a 
mixture of 1,4-dioxane/1 M HCl (aq) (1:1, 2 mL) and heated at 80 °C for 3.5 h, then at rt overnight 
(TLC analysis (MeOH/DCM 1:9) indicated complete N-Boc deprotection after 1.5 h). Heating was 
continued under reflux for a further 5 h, before cooling and concentration under reduced pressure, 
to give 205 mg of pale yellow solid (quantitative yield).  1H NMR (400 MHz, DMSO) δ 14.75 (s, 
1H), 9.14 (s, 1H), 8.45 (s, 3H), 7.77 (ddd, J = 13.7, 9.1, 4.3 Hz, 1H), 7.56–7.31 (m, 3H), 7.21 (d, J 
= 8.3 Hz, 2H), 5.90 (d, J = 4.0 Hz, 2H), 3.97 (s, 2H); 13C NMR (101 MHz, DMSO) δ 177.04, 
165.18, 158.46 (d, JCF = 261.7 Hz), 152.63, 147.97 (d, JCF = 262.4 Hz), 137.80, 131.87, 130.23, 
126.15, 120.50, 119.70 (d, JCF = 23.1 Hz), 119.04, 113.35 (d, JCF = 13.3 Hz), 109.46, 85.09, 83.04, 
60.31 (d, JCF = 4.2 Hz), 28.93; m/z MS (TOF ES
+) C20H15F2N2O3 [MH]
+ calcd 369.1; found 369.1; 
LC-MS tR: 4.36. 
Ethyl 3-(dimethylamino)-2-(2-fluorobenzoyl)acrylate (24).
40 Ethyl-(2-fluorobenzyl)acetate 
(23) (1.04 g, 4.95 mmol) was dissolved in DMF (1 mL) and N,N-dimethylformamide, dimethyl 
acetal (627 mg, 5.26 mmol, 1 eq) added. The mixture was heated at 100 °C in the microwave 
reactor for 30 min, before pouring onto ice water (200 mL), and stirring for 5 min. The aqueous 
slurry was then extracted with Et2O (20 mL), before saturating the aqueous layer with NaCl and 
extracting again with Et2O (2 x 20 mL). The combined organic layers were washed with brine (30 
mL) before concentration to give 1.185 g of yellow oil (90%). 1H NMR (400 MHz, CDCl3) δ 7.75 
(s, 1H), 7.59 (s, 1H), 7.45 – 7.31 (m, 1H), 7.16 (ddd, J = 7.6, 0.9 Hz, 1H), 7.01 (ddd, J = 10.3, 8.3, 
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 0.8 Hz, 1H), 3.95 (q, J = 7.1 Hz, 2H), 3.28 (s, 3H), 2.90 (s, 3H), 0.88 (t, J = 7.1 Hz, 3H); m/z MS 
(TOF ES+) C14H17FNO3 [MH]
+ calcd 266.1; found 266.2.1; LC-MS tR: 5.66. 
Ethyl 1-(4-methoxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (25a).
40
 Ethyl 3-
(dimethylamino)-2-(2-fluorobenzoyl)acrylate (24) (100 mg, 0.38 mmol) and p-anisidine (47 mg, 
0.38 mmol, 1 eq) were dissolved in dry DMF (2 mL) and heated at 140 °C in the microwave reactor 
for 1 h. TLC analysis (EtOAc/PE 1:1) indicated partial progression, so the mixture was heated at 
140 °C (oil bath) over the weekend. LC-MS analysis after this time indicated only 1 major peak, the 
mixture was poured on to ice water, and the resulting precipitate filtered, washed with water, PE 
and dried, to give 87 mg of pale brown solid (71%). 1H NMR (400 MHz, CDCl3) δ 8.55 (dd, J = 
8.0, 1.4 Hz, 1H), 8.50 (s, 1H), 7.51 (ddd, J = 8.6, 7.1, 1.6 Hz, 1H), 7.45–7.37 (m, 1H), 7.37–7.28 
(m, 2H), 7.16–7.04 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 3.92 (s, 3H), 1.40 (t, 
J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.59, 165.95, 160.61, 149.25, 141.14, 133.52, 
132.40, 128.70, 128.62, 127.65, 125.33, 117.85, 115.55, 111.39, 61.08, 55.88, 14.59; m/z MS (TOF 
ES+) C19H18NO4 [MH]
+ calcd 324.1; found 324.2; LC-MS tR: 5.27. 
Ethyl 1-([1,1'-biphenyl]-4-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (25b). Ethyl 3-
(dimethylamino)-2-(2-fluorobenzoyl)acrylate (24) (100 mg, 0.38 mmol) and 4-aminobiphenyl (64 
mg, 0.38 mmol, 1 eq) were dissolved in dry DMF (2 mL) and heated at 140 °C (oil bath) over the 
weekend. LC-MS analysis after this time indicated only 1 major peak, the mixture was poured on to 
ice water, and the resulting precipitate filtered, washed with water, PE and dried, to give 85 mg of 
yellow solid (61%). 1H NMR (400 MHz, CDCl3) δ 8.64–8.50 (m, 2H), 7.88–7.77 (m, 2H), 7.72–
7.64 (m, 2H), 7.64–7.48 (m, 5H), 7.48–7.36 (m, 2H), 7.08 (dd, J = 13.6, 4.9 Hz, 1H), 4.41 (q, J = 
7.1 Hz, 2H), 1.41 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.58, 165.83, 148.84, 
143.27, 140.75, 139.83, 139.48, 132.50, 129.27, 129.16, 128.63, 128.46, 127.87, 127.74, 127.39, 
125.47, 117.81, 111.63, 61.13, 14.60; m/z MS (TOF ES+) C24H20NO3 [MH]
+ calcd 370.1; found 
370.2; LC-MS tR: 5.77. 
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 1-(4-Methoxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (26a). Ethyl 1-(4-
methoxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (25a) (68 mg, 0.21 mmol) was 
hydrolysed according to general procedure D. On acidification of the aqueous layer during workup, 
a pink precipitate formed. This was collected by filtration (vacuum) and washed with water and PE, 
before drying to give 46 mg of pink solid (74%). 1H NMR (400 MHz, CDCl3) δ 14.92 (s, 1H), 8.80 
(s, 1H), 8.56 (dd, J = 8.1, 1.3 Hz, 1H), 7.68 (ddd, J = 8.7, 7.1, 1.6 Hz, 1H), 7.57 (ddd, J = 8.1, 7.1, 
1.0 Hz, 1H), 7.41–7.28 (m, 2H), 7.17 (d, J = 8.5 Hz, 1H), 7.15–7.05 (m, 2H), 3.93 (s, 4H); 13C 
NMR (101 MHz, CDCl3) δ 178.92, 167.11, 161.03, 149.04, 141.64, 133.90, 132.77, 128.36, 
126.90, 126.49, 126.07, 118.72, 115.71, 109.02, 55.94; m/z MS (TOF ES+) C17H14NO4 [MH]
+ calcd 
296.1; found 296.2; LC-MS tR: 5.25. 
1-([1,1'-Biphenyl]-4-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (26b). Ethyl 1-([1,1'-
biphenyl]-4-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate (25b) (68 mg, 0.18 mmol) was 
hydrolysed according to general procedure D. On extracting the reaction mixture with Et2O, the 
lithium salt of the product was found to suspend in the organic layer. This was collected by 
filtration (vacuum), before suspending in 2 M HCl (aq) (10 mL), and extracting the acidic suspension 
with DCM (2 x 10 mL). Concentration of the DCM layers gave 35 mg of pale yellow solid (57%). 
1H NMR (400 MHz, CDCl3) δ 14.88 (s, 1H), 8.86 (s, 1H), 8.59 (dt, J = 5.1, 2.5 Hz, 1H), 7.93–7.79 
(m, 2H), 7.76–7.64 (m, 3H), 7.60 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 7.57–7.39 (m, 5H), 7.27 (d, J = 
8.1 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 178.96, 166.99, 148.68, 143.94, 141.27, 139.21, 
139.10, 134.01, 129.32, 129.31, 128.65, 127.54, 127.42, 127.01, 126.61, 126.11, 118.68, 109.23; 
m/z MS (TOF ES+) C22H16NO3 [MH]
+ calcd 342.1; found 342.2; LC-MS tR: 5.72. 
Ethyl 1-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylate (27) Ethyl 3-(dimethylamino)-2-(2-fluorobenzoyl)acrylate (24) (500 mg, 1.88 mmol), 
N-Boc-(4-aminomethyl)piperidine (404 mg, 1.88 mmol, 1 eq) and Cs2CO3 (735 mg, 2.26 mmol, 1.2 
eq) were dissolved in dry DMF (10 mL) under an atmosphere of nitrogen gas. The mixture was 
heated at 100 °C (oil bath) for 6.5 h, after which time TLC analysis (EtOAc/PE 6:4) indicated 
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 disappearance of starting material. The mixture was cooled to rt, before diluting with ice water and 
stirring for 30 min. The resulting precipitate was collected by filtration (vacuum) to give 619 mg of 
off-white solid (79%). 1H NMR (400 MHz, CDCl3) δ 8.56 (dd, J = 8.1, 1.5 Hz, 1H), 8.40 (s, 1H), 
7.70 (ddd, J = 8.6, 7.1, 1.6 Hz, 1H), 7.46 (td, J = 7.6, 0.8 Hz, 1H), 7.41 (d, J = 8.5 Hz, 1H), 4.41 (q, 
J = 7.1 Hz, 2H), 4.34 – 3.84 (m, 4H), 2.63 (t, J = 12.2 Hz, 2H), 2.09 (ddt, J = 15.4, 7.6, 3.8 Hz, 1H), 
1.60 (d, J = 17.3 Hz, 2H), 1.46 (s, 9H), 1.42 (t, J = 7.1 Hz, 3H), 1.37–1.10 (m, 2H); 13C NMR (101 
MHz, CDCl3) δ 174.32, 166.09, 154.70, 149.49, 139.07, 132.76, 129.51, 128.49, 125.34, 115.67, 
110.94, 79.99, 61.17, 59.33, 43.40, 35.69, 29.83, 28.56, 14.60; m/z MS (TOF ES+) C23H31N2O5 
[MH]+ calcd 415.2; found 415.3; LC-MS tR: 5.42. 
1-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic 
acid (28). Ethyl 1-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylate (27) (250 mg, 0.60 mmol) was dispersed in THF/water (1:1, 6 mL) and the flask 
atmosphere purged with nitrogen gas. LiOH.H2O (101 mg, 2.41 mmol, 4 eq) was added, and the 
mixture stirred at rt overnight. TLC analysis (MeOH/DCM 5:95) indicated conversion was 
complete. The mixture was diluted with water (20 mL) and washed with Et2O (30 mL), before 
careful acidification (~pH 4-5) by dropwise addition of 2 M HCl (aq), causing a precipitate to form. 
This was collected by filtration (vacuum) to give 202 mg of off-white solid (87%). 1H NMR (400 
MHz, CDCl3) δ 14.85 (s, 1H), 8.69 (s, 1H), 8.58 (dd, J = 8.1, 1.5 Hz, 1H), 7.87 (ddd, J = 8.7, 7.2, 
1.6 Hz, 1H), 7.68–7.54 (m, 2H), 4.19 (s, 4H), 2.63 (t, J = 12.0 Hz, 2H), 2.11 (dtd, J = 15.4, 7.7, 3.9 
Hz, 1H), 1.83–1.52 (m, J = 13.5 Hz, 2H), 1.45 (d, J = 7.0 Hz, 9H), 1.32 (dt, J = 23.1, 13.5 Hz, 2H); 
13C NMR (101 MHz, CDCl3) δ 178.62, 167.03, 154.66, 148.79, 139.62, 134.26, 127.79, 126.85, 
126.48, 116.46, 108.82, 80.13, 59.94, 43.06, 36.02, 29.82, 28.54; m/z MS (TOF ES+) C21H27N2O5 
[MH]+ calcd 387.2; found 387.2; LC-MS tR: 5.45. 
4-Oxo-1-(piperidin-4-ylmethyl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride (29). 
1-((1-(tert-Butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
(28) (155 mg, 0.40 mmol) was dissolved in DCM (2 mL) with stirring at rt, before addition of 4M 
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 HCl in 1,4-dioxane (2 mL). The mixture was stirred at rt for 1 h, before addition of PE, followed by 
collection of the resulting precipitate by filtration (vacuum). The collected solid was further washed 
with PE, before drying to give 149 mg of off-white solid (quantitative yield). 1H NMR (400 MHz, 
DMSO) δ 9.18–8.95 (m, J = 16.9 Hz, 2H), 8.89–8.62 (m, J = 10.1 Hz, 1H), 8.41 (dd, J = 8.1, 1.5 
Hz, 1H), 8.11 (d, J = 8.7 Hz, 1H), 7.99 (ddd, J = 8.7, 7.1, 1.6 Hz, 1H), 7.69 (dd, J = 11.2, 3.9 Hz, 
1H), 4.56 (d, J = 7.4 Hz, 2H), 3.23 (d, J = 12.5 Hz, 2H), 2.75 (q, J = 12.3 Hz, 2H), 2.16 (ddd, J = 
11.2, 7.5, 3.6 Hz, 1H), 1.71 (d, J = 12.8 Hz, 2H), 1.60–1.38 (m, 2H); 13C NMR (101 MHz, DMSO) 
δ 177.83, 166.08, 149.81, 139.52, 134.30, 126.43, 125.97, 125.61, 118.45, 107.40, 57.13, 42.36, 
32.69, 25.50; m/z MS (TOF ES+) C16H19N2O3 [MH]
+ calcd 287.1; found 287.2; LC-MS tR: 3.70. 
Ethyl 4-oxo-1-(piperidin-4-ylmethyl)-1,4-dihydroquinoline-3-carboxylate hydrochloride 
(30). Ethyl 1-((1-(tert-butoxycarbonyl)piperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylate (27) (342 mg, 0.83 mmol) was dissolved in DCM (2 mL) and stirred at rt before 
addition of 4M HCl in 1,4-dioxane (2 mL). The mixture was stirred at rt for 1 h before addition of 
PE and attempted collection of the resulting precipitate by filtration (vacuum). However, the 
product was found to be hygroscopic, so the solid was redissolved in MeOH/DCM and combined 
with the filtrate, before concentration under reduced pressure, to give 325 mg of off-white solid 
(quantitative yield). 1H NMR (400 MHz, DMSO) δ 9.11 (d, J = 10.1 Hz, 1H), 8.90 (d, J = 9.9 Hz, 
1H), 8.68 (s, 1H), 8.26 (dd, J = 8.0, 1.5 Hz, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.83–7.74 (m, 1H), 7.49 
(t, J = 7.5 Hz, 1H), 4.35 (d, J = 7.3 Hz, 2H), 4.23 (q, J = 7.1 Hz, 2H), 3.23 (d, J = 12.3 Hz, 2H), 
2.86 – 2.64 (m, 2H), 2.13 (dd, J = 9.1, 5.8 Hz, 1H), 1.70 (d, J = 12.8 Hz, 2H), 1.50 (td, J = 15.6, 3.6 
Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, DMSO) δ 172.79, 164.78, 149.74, 139.00, 
132.72, 128.35, 126.46, 124.96, 117.54, 109.70, 59.82, 56.47, 42.38, 32.53, 25.58, 14.36;  m/z MS 
(TOF ES+) C18H23N2O3 [MH]
+ calcd 315.2; found 315.2; LC-MS tR: 3.67. 
1-((1-Benzylpiperidin-4-yl)methyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (31). Ethyl 
4-oxo-1-(piperidin-4-ylmethyl)-1,4-dihydroquinoline-3-carboxylate hydrochloride (30) (80 mg, 
0.23 mmol), K2CO3 (79 mg, 0.57 mmol, 2.5 eq), BnBr (47 mg, 0.28 mmol, 1.2 eq) were dispersed 
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 in MeCN (2 mL) and stirred at rt overnight. MeCN was removed under reduced pressure, and the 
residue dispersed in water, causing a precipitate to form. This was collected by filtration (vacuum), 
and washed with PE to give 60 mg of off-white solid. This was purified by FCC (MeOH/DCM 
0:100 to 10:90) to give 48 mg of glassy solid. This was taken up in water/THF (1:1, 4 mL), and the 
vessel purged with nitrogen gas, before addition of LiOH.H2O (39 mg, 0.92 mmol, 4 eq). The 
mixture was stirred at rt overnight, before diluting with water (20 mL) and washing with Et2O (20 
mL). The aqueous layer was then neutralised with careful addition of 2M HCl (aq), before extraction 
with EtOAc (3 x 20 mL). Finally, concentration of the EtOAc layers gave 35 mg of off-white solid 
(40%). 1H NMR (400 MHz, DMSO) δ 15.23 (s, 1H), 9.01 (s, 1H), 8.40 (dd, J = 8.1, 1.5 Hz, 1H), 
8.10 (d, J = 8.7 Hz, 1H), 7.97 (ddd, J = 8.7, 7.0, 1.6 Hz, 1H), 7.67 (t, J = 7.2 Hz, 1H), 7.39–7.15 (m, 
5H), 4.50 (d, J = 7.4 Hz, 2H), 3.41 (s, 2H), 2.78 (d, J = 11.4 Hz, 2H), 1.95–1.62 (m, 3H), 1.56 – 
1.27 (m, 4H); 13C NMR (101 MHz, DMSO) δ 177.73, 166.07, 149.64, 139.54, 137.41, 134.27, 
128.62, 128.10, 126.79, 126.36, 125.91, 125.51, 118.45, 107.26, 62.13, 58.12, 52.44, 34.95, 28.70; 
m/z MS (TOF ES+) C23H25N2O3 [MH]
+ calcd 377.2; found 377.2; LC-MS tR: 4.16. 
4-Oxo-1-((1-(phenylcarbamoyl)piperidin-4-yl)methyl)-1,4-dihydroquinoline-3-carboxylic 
acid (32). Ethyl 4-oxo-1-(piperidin-4-ylmethyl)-1,4-dihydroquinoline-3-carboxylate hydrochloride 
(30) (80 mg, 0.23 mmol) was dispersed in DCM (2 mL), with addition of DIPEA (0.060 mL, 0.35 
mmol, 1.5 eq) and stirred at rt, before addition of phenyl isocyanate (0.027 mL, 0.25 mmol, 1.1 eq). 
The mixture was stirred at rt overnight. Further phenyl isocyanate (0.2 eq) with stirring at rt for a 
further 3 h, before diluting the reaction mixture with EtOAc (30 mL) and washing with 2 M NaOH 
(aq) (20 mL), 2M HCl (aq) (20 mL) and brine (20 mL). The organic layer was concentrated and 
further purified by FCC (eluent MeOH/DCM 0:100 to 10:90) to give 88 mg of yellow solid. This 
was taken up in water/THF (1:1, 4 mL), and the vessel purged with nitrogen gas, before addition of 
LiOH.H2O (39 mg, 0.92 mmol, 4 eq). The mixture was stirred at rt overnight, before diluting with 
water (20 mL) and washing with Et2O (20 mL). The aqueous layer was then acidified (~pH 4) with 
2M HCl (aq), causing a precipitate to form. This was collected by filtration (vacuum) to give 20 mg 
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 of off-white solid (22%). 1H NMR (400 MHz, DMSO) δ 15.24 (s, 1H), 9.05 (s, 1H), 8.46 (s, 1H), 
8.42 (dd, J = 8.1, 1.4 Hz, 1H), 8.14 (d, J = 8.7 Hz, 1H), 7.99 (ddd, J = 8.6, 7.1, 1.4 Hz, 1H), 7.69 
(dd, J = 7.5 Hz, 1H), 7.44 (d, J = 7.6 Hz, 2H), 7.21 (dd, J = 7.9 Hz, 2H), 6.91 (dd, J = 7.3 Hz, 1H), 
4.53 (d, J = 7.5 Hz, 2H), 4.13 (d, J = 13.4 Hz, 2H), 2.68 (t, J = 12.1 Hz, 2H), 2.24–1.97 (m, 1H), 
1.54 (d, J = 10.9 Hz, 2H), 1.28 (ddd, J = 19.5, 9.8, 6.2 Hz, 2H); 13C NMR (101 MHz, DMSO) δ 
177.78, 166.09, 154.73, 149.68, 140.68, 139.58, 134.28, 128.23, 126.38, 125.94, 125.56, 121.54, 
119.50, 118.47, 107.32, 57.81, 43.47, 35.12, 28.63; m/z MS (TOF ES+) C23H24N3O4 [MH]
+ calcd 
406.2; found 406.2; LC-MS tR: 5.13. 
 
Pharmacology. 
Radioligand binding assays. FlpInCHO cells stably expressing the human M1 muscarinic 
acetylcholine receptor (FlpInCHO-hM1 mAChR) were generated as described previously
41 and 
maintained in DMEM containing 5% FBS under humidified conditions at 37°C and 5% CO2. 
Radioligand binding experiments were performed on whole cells, seeded at 20,000 cells per well in 
complete DMEM into 96-well ISOPLATE TC plates. Next, cells were allowed to grow for 8 hours 
at 37 °C, then serum starved overnight. Following a wash with phosphate-buffered saline (100 µl) 
the cells were then resuspended in binding buffer (10 mM HEPES, 100 mM NaCl, 10 mM MgCl2, 
pH 7.4).  Assays were performed in a total volume of 200 µl with a 1/10 dilution of drug, for a 
duration of 4 hours at 4 °C.  Assays were terminated by buffer removal followed by rapid washing, 
twice, with ice-cold 0.9% NaCl (100 µl).  Plates were allowed to dry inverted for 30 min; OptiPhase 
Supermix scintillation cocktail (100 µl) was added, plates were sealed (TopSealTM), and 
radioactivity was measured in a MicroBeta2 LumiJET microplate counter. All inhibition binding 
experiments were performed with 0.1 nM [3H]-NMS (KD concentration) in presence of increasing 
concentrations of ACh with or without increasing concentrations of BQCA analogues. 
Intracellular calcium mobilisation assays. On the day prior to the experiment, FlpInCHO-hM1 
mAChR cells were seeded at 20,000 cells per well (100 µL final volume per well) into clear 96-well 
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 plates in DMEM containing 5% FBS and incubated 8 hours under humidified conditions at 37°C 
and 5% CO2 prior serum starving the cells overnight. On the day of the experiment, the assay plates 
were washed once with 100 µL per well of phosphate buffered saline. The cells were then incubated 
with Ca2+ assay buffer (150 mM NaCl, 2.6 mM KCl, 1.18 mM MgCl2·6H2O, 10 mM D-glucose, 10 
mM HEPES, 2.2 mM CaCl2·2H2O, 0.5% (w/v) bovine serum albumin (BSA), and 4 mM 
Probenecid, pH = 7.4) containing 1 µM Fluo-4-AM for 1 hour under humidified conditions at 37°C 
and 0% CO2. Each assay plate was then loaded into a FLEXstation™ (Molecular Devices Inc., 
Sunnyvale, CA) with its stock compound plate. The FLEXstation measured fluorescence over a 100 
second time period using 485 nm excitation and 520 nm emission wavelengths and performed the 
addition of drugs (1/10 dilution) at the 20 second time point. For all interaction studies, ACh and 
BQCA (or its analogue) were co-added (simultaneously) at 20 seconds. For each, the peak of 
maximum florescence between the time 20 to 100 seconds was chosen and corrected to the baseline 
(fluorescence from time 0 to 19 seconds), then normalised to 100 µM ATP as internal control. 
Data analysis. Competition binding curves between [3H]NMS and ACh in the absence or presence 
of BQCA or its analogues, were fitted to the allosteric ternary complex model as described 
previously7. Competition-binding curves between [3H]NMS and ACh in the absence or presence of 
BQCA or analogues were fitted to the following allosteric ternary complex model (equation 1): 
Y =
A[ ]
A[ ] + KAKB
α ' B[ ] + KB
 
  
 
  
1 +
I[ ]
K I
+
B[ ]
KB
+
α I[ ] B[ ]
K IKB
 
  
 
        (1) 
where Y is percentage (vehicle control) binding, [A], [B], and [I] are the concentrations of 
[3H]NMS, BQCA (or analogues) and ACh respectively, KA and KB are the equilibrium dissociation 
constants of [3H]NMS and BQCA, respectively, KB is the equilibrium dissociation constant of CCh 
and α′ and α are the cooperativities (or analogues) between BQCA and [3H]NMS or CCh 
respectively. Values of α (or α′) > 1 denote positive cooperativity; values < 1 (but > 0) denote 
negative cooperativity, and values =1 denote neutral cooperativity. 
Page 55 of 73
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Functional data were analysed using an operational model of allosterism and agonism according to 
equation 2: 10,42 
E =
Em τA[A] KB + αβ[B]( )+ τB[B]KA( )
n
[A]KB + KAKB + [B]KA +α[A][B]( )
n
+ τ A[A] KB + αβ[B]( )+ τB[B]KA( )
n
    (2) 
where Em is the maximum possible cellular response, [A] and [B] are the concentrations of 
orthosteric and allosteric ligands, respectively, KA and KB are the equilibrium dissociation constant 
of the orthosteric and allosteric ligands, respectively, τA and τB are operational measures of 
orthosteric and allosteric ligand efficacy (which incorporate both signal efficiency and receptor 
density), respectively, α is the binding cooperativity parameter between the orthosteric and 
allosteric ligand, and β denotes the magnitude of the allosteric effect of the modulator on the 
efficacy of the orthosteric agonist.  In all instances, the equilibrium dissociation constant of each 
agonist and BQCA (or analogues) was fixed to that determined from the binding assays. 
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 Scheme 1: Synthesis of BQCA analogues with varied 5- and 8- substituents
a
 
 
aReagents and conditions: (a) diethylethoxymethylene malonate, 100-120 °C, 71-86%; (b) 
diethylethoxymethylene malonate, Et3N, 100 °C, 79%; (c) Eaton’s reagent, 90-100 °C, 35-84%; (d) 
H2, 10% Pd/C, EtOH, 100%; (e) alkyl halide, KI, K2CO3, DMF, rt, 32-86%; (f) 1,4-dioxane/HCl(aq), 
reflux, 62-90%; (g) LiOH.H2O, THF, water, rt, 49-98%; (h) i. 1 M NaOH(aq), 1,4-dioxane, 80 °C; ii. 
LiOH.H2O, reflux; iii. microwave 160 °C, 1 hour; 53%. 
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 Scheme 2: Synthesis of amide/N-acyl-sulfonamide derivatives of 5,8-difluoro-1-(4-
methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
a
 
   
aReagents and conditions: (a) i. DCM, 0 °C; ii. Oxalyl chloride, DMF; (b) amine or amine 
hydrochloride + TEA, DCM, 18-83%; (c) i. HCTU, amine, DMF; ii. DIPEA, DCM, 62-100%; (d) i. 
methanesulfonamide, DCM, 0 °C; ii. TEA, 0 °C to rt; 39%. 
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 Scheme 3 Synthesis of amide and acid isostere analogues of 5,8-difluoro-1-(4-methoxybenzyl)-
4-oxo-1,4-dihydroquinoline-3-carboxylic acid
a
 
 
aReagents and conditions: (a) 40% MeNH2 (aq), EtOH, rt, 83%; (b) Ethanolamine, EtOH, rt, 88%; (c) 
28-30% NH3 (aq), EtOH, rt, 88%; (d) i. PdCl2, MeCN, water, MeOH, THF, rt; ii. 50 °C, 35%; (e) 
NaN3, TEA.HCl, toluene, reflux, 38%; (f) Ac2O, pyridine, 100 °C, 64%. 
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 Scheme 4 Synthesis of 5,8-difluoro-1-(substituted-benzyl)-4-oxo-1,4-dihydroquinoline-3-
carboxylic acid analogues
a
 
 
aReagents and conditions: (a) alkyl halide, KI, K2CO3, DMF, rt, 67-75%; (b) 2 M HCl (aq), 1,4-
dioxane, 80 °C to reflux, 91-96%; (c) Boc2O, water, rt, 96%; (d) 4-iodobenzyl alcohol, TEA, CuI, 
PdCl2(PPh3)2, THF, 42%; (e) PPh3, CBr4, DCM, 0 °C to rt, 55%; (f) 1 M HCl (aq), 1,4-dioxane, 80 
°C to reflux, 100%. 
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 Scheme 5 Synthesis of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing N-aryl or N-
(substituted piperidine-4-methyl) groups
a
 
 
aReagents and conditions:  (a) N,N-dimethylformamide, dimethyl acetal, DMF, microwave 100 °C, 
30 min, 90%; (b) substituted aniline, dry DMF, 140 °C, 61-71%; (c) LiOH.H2O, THF, water, rt, 57-
74%; (d) N-Boc-(4-aminomethyl)piperidine, dry DMF, 100 °C, 79%; (e) LiOH.H2O, THF, water, 
rt, 22-87%; (f) 4 M HCl/1,4-dioxane, DCM, 100%; (g) BnBr, K2CO3, MeCN, rt; (h) phenyl 
isocyanate, DIPEA, DCM, rt. 
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Figure 1. Pharmacological characterization of BQCA and 5a in radioligand binding and 
calcium mobilization assays. (A and B) Radioligand binding experiments using M1-expressing 
CHO cells in presence of a KD concentration of the radiolabelled antagonist  [
3H]-NMS (0.1 nM), 
increasing concentrations of ACh with or without increasing concentrations of either BQCA (A) or 
5a (B). (C, D and E) Calcium mobilization experiments. (C) Increasing concentration of ACh, 
BQCA and 5a alone. (D and E) Increasing concentrations of ACh with or without increasing 
concentrations of either BQCA (D) or 5a (E). Values represent the mean ± S.E.M. from at least 
three to four experiments performed in duplicate. 
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 Table 1: Binding and functional parameters for analogues of BQCA with varying 5- and 8- substituents, bearing an N-(4-
methoxybenzyl) or N-(4-phenylbenzyl) pendant
a 
 
 R
1
 R
2
 R
3
 R
4
 pKB Logα (α) LogτB (τB) Logαβ (αβ) 
BQCA H H OMe H 4.72 ± 0.07 2.60 ± 0.11 (400) 1.45 ± 0.09 (28) 2.72 ± 0.13 (525) 
3a F F OMe Et 5.12 ± 0.15 0.18 ± 0.09 (1.5)   
3b F OMe OMe Et 4.82 ± 0.28 −0.10 ± 0.27 (1)   
3c H OMe OMe Et 4.51 ± 0.04 −0.99 ± 1.04 (0.1)   
3d OMe H OMe Et 4.22 ± 0.06 1.19 ± 0.15 (16)   
4a F F Ph Et 3.75 ± 0.10 0.63 ± 0.24 (4)   
4b F OMe Ph Et 5.32 ± 0.11 0.59 ± 0.12 (4)   
4c H OMe Ph Et 4.08 ± 0.07 0.69 ± 0.20 (5)   
4d OMe H Ph Et 5.16 ± 0.15 0.70 ± 0.14 (5)   
5a F F OMe H 4.96 ± 0.13 2.62 ± 0.10(420) 2.18 ± 0.06 (150) 2.31 ± 0.28 (205) 
5b F OMe OMe H 4.86 ± 0.03 1.31 ± 0.09 (20)   
5c H OMe OMe H 4.75 ± 0.05 1.68 ± 0.10 (48)   
5d OMe H OMe H 4.62 ± 0.12 2.20 ± 0.14 (160) 1.75 ± 0.17 (55)  
6a F F Ph H 5.36 ± 0.10 3.16 ± 0.13 (1450) 2.37 ± 0.20 (240) 2.87 ± 0.24 (740) 
6b F OMe Ph H 5.84 ± 0.04 0.87 ± 0.12 (7)   
6c H OMe Ph H 5.71 ± 0.05 0.98 ± 0.11 (10)   
6d OMe H Ph H 5.67 ± 0.10 1.70 ± 0.10 (50) 1.92 ± 0.10 (85)  
7 OH F Ph H 5.55 ± 0.17 2.41 ± 0.26 (257)   
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Table 2: Binding and functional parameters for analogues of 5,8-difluoro-1-(4-
methoxybenzyl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing amide or acid isostere 
groups 
a
 
 
 X pKB Logα (α) LogτB (τB) Logαβ (αβ) 
      
11 CONH2 5.17 ± 0.12 1.51 ± 0.12 (32)   
10a CONHCH3 4.92 ± 0.12 0.28 ± 0.10 (2)   
8a CONHEt 5.78 ± 0.18 0.17 ± 0.10 (1.5)   
8b CON(CH3)2 4.48 ± 0.19 0.85 ± 0.15 (7)   
8c 
 
4.80 ± 0.37 −0.01 ± 0.16 (1.0)   
8d 
 
4.63 ± 0.21 1.75 ± 0.20 (56) 1.25 ± 0.20 (18)  
8e 
 
5.07 ± 0.15 1.45 ± 0.16 (28)   
8f 
 
4.99 ± 0.07 2.22 ± 0.10 (170) 2.36 ± 0.06 (230) 2.92 ± 0.06 (840) 
10b 
 
4.65 ± 0.17 0.96 ± 0.12 (9)   
8g 
 
4.97 ± 0.20 0.29 ± 0.13 (2)   
8h 
 
4.71 ± 0.24 1.26 ± 0.21 (18)   
12 CN 4.66 ± 0.20 0.74 ± 0.17 (6)   
13 
 
4.97 ± 0.18  1.89 ± 0.17 (78) 0.99 ± 0.07 (10)  
14 
 
4.35 ± 0.07 1.04 ± 0.57 (11)   
8i 
 
4.80 ± 0.20 1.52 ± 0.17 (33)   
9 
 
4.63 ± 0.06 1.47 ± 0.19 (30)   
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Table 3: Binding and functional parameters for 5,8-difluoro-1-(substituted-benzyl)-4-oxo-1,4-
dihydroquinoline-3-carboxylic acid analogues
a 
 
 R
3A
 R
3B
 pKB Logα (α) LogτB (τB) Logαβ (αβ) 
16a 2-Ph H 5.00 ± 0.04 1.87 ± 0.08 (74) 1.10 ± 0.23 (13)  
16b 3-Ph H 5.55 ± 0.16 1.64 ± 0.15 (44)   
22 - 
 
4.96 ± 0.03 2.29 ± 0.07 (195) 
 
1.82 ± 0.14 (65) 2.35 ± 0.09 (225) 
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Table 4: Binding and functional parameters for 4-oxo-1,4-dihydroquinoline-3-carboxylic acid 
derivatives bearing N-aryl or N-(substituted piperidine-4-methyl) groups
a
 
 
 X pKB LogαACh 
26a 
 
4.65 ± 0.21 0.52 ± 0.15 (3) 
26b 
 
4.73 ± 0.26 −0.07 ± 0.10 (1) 
28 
 
4.70 ± 0.10 0.45 ± 0.09 (3) 
29 
 
4.82 ± 0.12 0.17 ± 0.10 (1.5) 
31 
 
5.13 ± 0.05 −0.02 ± 0.22 (1) 
32 
 
4.66 ± 0.08 0.99 ± 0.27 (10) 
 
 
NH.HCl
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